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ABSTRACT  
   
 This study explores how newspapers framed the weight-loss drugs 
Xenical (orlistat) and Alli  (over-the-counter orlistat) during the time period of 
three months prior to their approvals by the U.S. Food and Drug Administration 
until one year after each became available on the market. As of June 2011, orlistat 
is the only weight-loss drug available for long-term use in the U.S.  Newspapers 
are influential sources of information about health issues. Agenda-setting, 
framing, and priming in news articles can have a powerful effect on public 
perceptions and behaviors.   
To conduct the content analysis, researchers first developed a codebook 
containing variables that described the sources of attribution and the features of 
each drug. They tested the codebook in a series of pilot tests to ensure inter-rater 
reliability. The sample of texts for the content analysis, drawn from LexisNexis 
Academic, contained 183 newspaper articles composed of 85 Xenical articles and 
98 Alli articles. The overlap was 25% for inter-rater reliability as well as intra-
rater reliability. Frequencies were tabulated using Predictive Analytics SoftWare, 
version 18.0.3.   
 Results demonstrated that Xenical and Alli were framed differently in 
some critical ways.  For example, there were twice as many quotes from the 
manufacturer for Alli than for Xenical. Researchers concluded that the reporting 
on Alli was heavily influenced by the manufacturer’s multi-media public relations 
campaign in the months prior to the market-release date.  
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CHAPTER 1 
INTRODUCTION  
  The objective of this research study is to examine the newspaper coverage 
in the United States of the weight-loss drugs Xenical  and Alli, which are 
branded versions of the generic weight-loss drug orlistat.  Orlistat works by 
preventing a portion of consumed dietary fat from being absorbed in the intestine.  
Xenical was approved by the Food and Drug Administration (FDA) in 1999 as a 
prescription-only weight-loss drug.  In contrast, Alli, was approved by the FDA as 
an over-the-counter weight-loss drug in February 2007.  
 In the United States, two-thirds of adults are classified as overweight 
(body mass index [BMI] = 25.0 – 29.9) or obese (BMI ≥ 30.0), as determined by 
weight (kg) divided by height squared (m2) (Centers for Disease Control and 
Prevention [CDC], 2009). Excess weight is associated with increased risks of 
coronary heart disease, type 2 diabetes mellitus, hypertension, dyslipidemia, 
stroke, major depressive disorder, and other diseases (CDC, 2009). For many 
consumers, the desire to lose weight for cosmetic reasons may be as compelling 
as the desire to avoid obesity-related conditions.   
 Before orlistat, the most widely used prescription-strength weight-loss 
drugs of the past two decades have been fen-phen, dexfenfluramine (branded as 
Redux), and sibutramine (branded as Meridia). Fen-phen was a combination of 
fenfluramine and phentermine, both of which had FDA-approval for short-term 
use.  During fen-phen’s heyday in the mid-1990s, many physicians considered 
these two drugs to have a symbiotic relationship for weight loss and began 
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prescribing them “off label” as a duo, even though the combined use of these 
drugs had never been vetted by the FDA (Colman, 2005).  In 1997, fenfluramine, 
half of fen-phen, was withdrawn voluntarily from the market upon the FDA’s 
request after the FDA received reports of cardiovascular and pulmonary damage.  
Dexfenfluramine, another appetite suppressant, had FDA approval for short-term 
use, but was recalled at the same time as fenfluramine due to similar adverse 
reports.  Meridia was a prescription weight-loss drug that was approved for long-
term use by the FDA in November 1997, the same year that fenfluramine and 
dexfenfluramine were recalled. Meridia modulates hunger and causes early satiety 
(Wadden, 2005) by inhibiting the reuptake of both serotonin and noradrenaline 
(Lean, 1997).  But sales of Meridia remained low due to its modest efficacy and 
relatively high cost (Saul, 2005).  Meridia was withdrawn from the market in 
October 2010 (FDA, 2010).   
 Many clinical studies were performed on orlistat to insure its efficacy and 
safety, as measured by markers of cardiovascular health outcome. As a 
gastrointestinal lipase inhibitor, orlistat does not act upon appetite or satiety 
controls but rather locally in the small intestine (Schwartz, 2008).  Unlike earlier 
weight-loss drugs such as fen-phen, Redux, and Meridia, orlistat was not 
associated with increased cardiovascular risks.  Xenical sales in the U.S. were 
$146 million in the first seven months of post-market release in 1999 (Goetzl, 
2000) but then declined quickly afterward and stayed low. Again, the modest 
amount of weight lost and the medication’s cost were deterrents to Xenical’s 
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commercial success.  In addition, consumers did not respond well to the side 
effect of fecal incontinence when dietary fat intake was exceeded.  
 In 2004, when GlaxoSmithKline (GSK) purchased the rights to market an  
over-the-counter version of orlistat for $100 million from Roche, the 
manufacturer of Xenical, Xenical sales in the U.S. were $122 million (Gaynor, 
2004).  GSK spent another $150 million on a large-scale multi-media branding 
and marketing program to launch Alli in the U.S. market in 2007 (Miley, 2009). 
GSK had high ambitions, expecting annual sales of Alli to reach $150 billion 
(Ostrov and Molina, 2007).  
 Media coverage of weight-loss drugs can be studied using the concept of 
framing, which has its roots in agenda-setting theory (McCombs and Shaw, 
1993).  Framing can be defined as choosing to emphasize certain pieces of 
information about an object, while simultaneously excluding certain other pieces 
of information, for the purpose of increasing the salience of the emphasized 
information to the consumer.  The more salient the information is, the more likely 
it is that the consumer will notice and remember it.  The way that a weight-loss 
drug is “framed” in the media influences public opinion about its usage and 
affects people’s decisions to request a doctor’s prescription for the drug or, as in 
the case of Alli, to buy the drug without needing a prescription.    
 The purpose of this research project was to explore and compare how 
newspapers used frames to present Xenical and Alli to the American public, 
starting from three months prior to their FDA approval dates to one year after 
their market release date. Newspapers play an important role in disseminating 
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information about health issues and influencing opinions and behaviors and are 
well-suited to research because of their broad availability and ease of access to 
archived data (Crawley, 2007). Researchers used LexisNexis Academic to locate 
a sample of appropriate articles. To determine frames, articles were coded for 
types of news sources used and the presence or absence of specific features of 
each weight-loss drug.   
 
 
 
 
   
 
 5 
 
CHAPTER 2 
METHODS  
 The source of the articles for the content analysis was LexisNexis® 
Academic (Reed Elsevier, Miamisburg, OH).  With more than 1,000 U.S. and 
foreign newspapers in its electronic archives, updated daily, LexisNexis 
Academic is the most comprehensive source of news articles available.   
LexisNexis Academic uses SmartIndexing Technology™, which begins 
when a panel of experts comprising academics and professionals convenes to 
form the database’s taxonomy (e.g., geographical locations, subject indices, key 
words or “tags”).  Using a Delphi approach, the panel assigns strata of 
“vocabulary terms” – including companies’ and individuals’ names and other 
selectors not usually considered vocabulary – to be applied to the database.  After 
each panel’s final taxonomy is determined, LexisNexis Academic assigns the 
panel’s terms to all newspaper articles in the database.   
The periodic convening of expert panels and SmartIndexing Technology 
ensures that LexisNexis Academic stays current with its terminology, allowing 
the database to be valid and reliable, and allows database users to best capture the 
sample of articles that interest them.  Updating LexisNexis Academic’s taxonomy 
minimizes search with “noise” articles that are irrelevant to the search – those 
written by journalists named Alli, for example – and keeps the database current 
(e.g., a search using the geography index with the now-antiquated term Soviet 
Union would yield articles about Russia). 
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Selectors change over time.  If expert-panel members search for 
newspaper articles and receive ambiguous results, LexisNexis Academic repeats 
the taxonomy-determining process with the cooperation of an expert panel.  With 
the updated taxonomy determined, LexisNexis Academic then applies these 
revisions to all newspaper articles in its archives, both prospectively and 
retrospectively.  In this manner, LexisNexis Academic ensures that the entirety of 
the database is labeled using the same taxonomy.  As an example, in 1995, 
Bombay, India, was renamed Mumbai.  A search using the narrow geographic 
index of Mumbai will yield pre-1995 results that referred to the city as Bombay, 
even though the word Mumbai does not appear in the newspaper article.  Search 
results, therefore, do not vary over time because of human bias.  
The date of the sample collection was November 23, 2008. Because the 
archives of LexisNexis Academic change over time as newspapers decide whether 
to provide full-text content of articles, searches for articles on other dates could 
yield different results.  U.S. newspaper articles regarding Alli® (GSK, 
Philadelphia, PA) or Xenical® (Genetech/Roche Group, South San Francisco, 
CA) were drawn from LexisNexis Academic by using a Power Search and its 
Natural Language search function.  The search statement contained the key terms 
Xenical or, later, Alli.   
Xenical was approved by the Food and Drug Administration (FDA) on 
April 23, 1999, and released to the market on April 26, 1999.  The range of the 
publication dates of newspaper articles was three months prior to FDA approval 
and during the 12 months following post-market release (i.e., January 23, 1999 
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through April 26, 2000).  The same search protocol was used for Alli, which was 
approved by the FDA on February 27, 2007, and released to the market on June 
14, 2007.  Beginning three months prior to FDA approval and ending 12 months 
post-market release, the date range was specified as November 27, 2006, through 
June 14, 2008, as the search dates for Alli-related articles. 
To increase the specificity of the results, the subject index “Medicine & 
Health,” not any narrower terms within that category, was selected as being 
relevant for the search.  The United States was selected as the geographical 
location and newspapers as the source for the search of Xenical- and Alli-related 
newspaper articles.  This search strategy yielded N = 226 Xenical-related articles 
and N = 384 Alli-related articles. 
Because the Dallas Morning News, Detroit Free Press, and the Chicago 
Tribune were excluded from the generic “newspaper” source category previously 
mentioned, the search was repeated identically except the source was changed to 
McClatchy-Tribune News Service or Global News Wire for the first two and the 
third newspapers, respectively.  Coverage of Xenical and Alli were minimal in 
these newspapers, but they were included to make the sample size more fully 
complete and because these three newspapers rank in the top-25 most-circulated 
articles, based on data from the Audit Bureau of Circulations (2008) for the six-
month period ending March 31, 2008.  The Wall Street Journal, although ranked 
second in the list of top-100 newspapers, was excluded from the sample because 
only article abstracts were available in LexisNexis Academic.  Similarly, the 
Arizona Republic, which ranked tenth on the top-100 newspapers list, provided 
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only abstracts of business-related articles to LexisNexis Academic when the data 
were collected.  The Sacramento Bee became available in LexisNexis Academic 
on January 1, 2002 and, thus, could not be a source of Xenical-related articles. 
Xenical or Alli had to be covered in at least one full paragraph within an 
article to be included in the study sample.  Additionally, an article had to have at 
least 200 words to be included in the content analysis.  Duplicate articles were 
included to account for multiple exposures to readers across the United States.  
Article corrections and those that mentioned either weight-loss drug in passing 
were excluded.  After cleaning both populations of articles, the final samples were 
85 and 97 articles for Xenical and Alli, respectively.  Date from the Audit Bureau 
of Circulations (2008) was used to determine if the articles in the samples were 
published in one of the top-100 newspapers based on weekday circulation for the 
six month period ending.  Those that were, along with their rank, are indicated in 
the tables.   
  Two independent coders used a grounded-theory approach to develop a 
content-analysis codebook.  Using a random number-generating program in 
Excel, articles were selected that were published prior to 1999 regarding Meridia® 
(Abbott Laboratories, Chicago, IL), a prescription-strength, weight-loss drug no 
longer sold in the United States, were used to determine relevant themes and key 
words until the coders reached a saturation point at which additional articles 
stopped contributing new ideas, concepts, and terms.     
Two independent evaluators (100% overlap) coded newspaper articles in a 
series of eight pilot studies until Cohen’s kappa (κ) > 0.70 for all variables, which 
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indicated that the variables had been defined and operationalized adequately.  
According to Helme et al. (2006), κ < 0.40 indicates marginal reliability, κ = 0.40 
– 0.75 indicates good reliability, and κ > 0.75 indicates excellent reliability. 
Cohen’s kappa is a conservative measure for calculating reliability in content 
analyses (Dutta and Boyd, 2007). Of the 21 variables for which a kappa score 
could be calculated, κ averaged 0.969 and κ ranged from 0.828 to 1.0. For 15 
variables, κ = 1.0. The two coders entered all coding data directly into Excel 
spreadsheets to avoid potential transcription errors from double recording (i.e., 
hand-writing data into spreadsheets and then typing the data into Excel) (Riffe, 
Lacy, and Fico, 2005).  When there was a conflict between the two coders, an 
independent researcher interceded to help resolve the conflict and update the 
codebook as needed. The iterative coding process helped to determine that some 
variables were irrelevant and should be excluded while new variables were added. 
The original version of the codebook contained 23 variables and the final version 
contained 30 variables. 
For the content analysis, Coder 1 coded 100% of the 85 Xenical articles 
and the 98 Alli articles.  For inter-rater reliability, Coder 2 coded 22 (25% of the 
85) Xenical articles and 25 (25% of the 98) Alli articles.  For intra-rater 
reliability, Coder 1 later re-coded 25% of the full sample of Xenical and Alli 
articles.  Researchers aimed for κ > 0.70.  For comparison, another content 
analysis used a sample of 395 articles with 20% overlap for inter-rater reliability 
and κ = 0.1 – 1.0, with a mean of 0.772 (Carlyle et al., 2008).   
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 Frequency distributions of the raw data were calculated using Predictive 
Analytics SoftWare (PASW, v. 18.0.3, Chicago, IL).  Frequencies were tabulated 
to demonstrate differences between the content of newspaper articles related to 
the two drugs.  
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CHAPTER 3 
RESULTS  
 The content analysis included a total of 183 articles, 85 Xenical articles 
and 98 Alli articles. For the Xenical articles, 27 of the 85 were published in 
newspapers that were not ranked in the Top 100.  Fifty percent of the Xenical 
articles that were ranked in the Top 100 (n = 58) were published by newspapers in 
the top nine. These newspapers were USA Today (#1), the New York Times (#3), 
The Daily News – New York, NY (#5), Washington Post (#7), and the Houston 
Chronicle (#9). There were no articles were published by the Wall Street Journal 
(#2) due to lack of availability of the full-text versions.  
 For the Alli articles, all 98 articles were published in newspapers that were 
ranked in the Top 100, ranging from number one (USA Today) to number 97 
(Albuquerque Journal).  Fifty percent of the 98 Alli articles were published by the 
top seven ranked newspapers: USA Today (#1), the New York Times (#3), The 
Daily News – New York, NY (#5), New York Post (#6) and Washington Post (#7).  
There were no articles were published by the Wall Street Journal (again due to 
lack of availability of the full-text versions).   
 In the sample, Xenical articles were most frequently published in April 
1999 (n = 31) and May 1999 (n= 30), reflecting the increased media production 
after Xenical’s April 23, 1999 FDA approval date and the April 26, 1999 market 
release date.  There was a dramatic decline in the number of articles published in 
June 1999 (n = 5). Alli articles were most frequently published in June 2007 (n = 
44), which is understandable given the June 14, 2007 market release date.  
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February 2007 had the second-highest number of Alli articles published  (n = 23), 
reflecting an increase in media production after the FDA approval date of 
February 27, 2007.  Media interest in Alli had fallen by the end of 2007, with very 
few articles being published in the first half of 2008 (n = 4).  
 About half of the Alli articles were published before the market release (n 
= 46) and half were published after the market release (n = 52), whereas with 
Xenical, 97.6% of the articles were published after the market release date (n = 
83).  
 In the category of news sources, there were several obvious differences. 
Alli articles contained twice as many quotes of attribution to dietitians, 
nutritionists, and registered dietitians (19%) than Xenical articles (9.4%).  For 
Xenical, there were dramatically more quotes of attribution to scientists (35.5%) 
than for Alli (3.1%).  Alli articles contained more than ten times as many more 
quotes of attributions to pharmacists (13.3%) relative to Xenical articles (1.2%). 
For Alli, there were more than twice as many quotes of attribution to the 
manufacturer (62.2%) than for Xenical (29.4%).  
 There were smaller differences in relation to the usage of other types of 
news sources.  Quotes of attribution from a layperson were mentioned slightly 
more often in Alli articles (33.7%) than Xenical articles (27.1%). Quotes of 
attribution from a physician were mentioned slightly more often in Xenical 
articles (35.3%) than in Alli articles (27.6%).  Quotes of attribution from 
psychotherapists were rarely mentioned in both Xenical articles (3.5%) and Alli 
articles (1.0%).  The regulatory role of the FDA was mentioned in the majority of 
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Xenical articles (76.5%) as well as the majority of Alli articles (81.6%), though 
slightly more often in Alli articles. 
 The weight-loss drugs were characterized differently in several critical 
ways.  Journalists neglected to report BMI standards in the majority of the 
articles; BMI standards were mentioned much less frequently in Alli articles 
(6.1%) than in Xenical articles (23.5%). Recommendations for changes in 
physical activity were mentioned in the majority of Alli articles (67.3%) but the 
opposite was true for Xenical (28.2%).  The cost of Alli was mentioned 69.4% of 
the articles but the cost of Xenical was mentioned in just 45.9% of the articles. 
   The differences in frequencies were smaller in relation to other 
characteristics of the weight-loss drugs.  Side effects were mentioned in almost 
every Xenical article (94.1%) and Alli article (93.9%). Recommendations for 
dietary changes were mentioned the majority of the time for both, though 
particularly more often for Alli (93.9%) relative to Xenical (76.5%). The drug’s 
mechanism was mentioned in most of the Xenical articles (94.1%) and most of 
the Alli articles (90.8%). A promise of specific weight loss was mentioned in the 
majority of Xenical articles (77.6%) and Alli articles (75.5%). Contraindications 
(stating who should not use the drug) were mentioned in less than one-third of 
Xenical articles (29.4%) and Alli articles (31.6%).  Recommendations for 
counseling were rarely mentioned in both the Xenical articles (1.2%) and the Alli 
articles (3.1%).
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Table 1 
Newspapers in the Sample of Xenical Articles (n = 85) 
Ranka Newspaper Daily 
Circulation 
Number of 
Xenical 
Articles  
Meanb 
Word 
Count 
- Charleston Gazette (West 
Virginia)  
 1 439 
- Ledger (Lakeland, Florida)   1 779 
- Lincoln Journal Star 
(Nebraska) 
 1 473 
- Portland Press Herald (Maine)  1 655 
- The Gazette (Colorado 
Springs)  
 1 663 
- The Herald (Rock Hill, SC)  1 220 
- The Washington Times  1 631 
- Idaho Falls Post Register 
(Idaho Falls, Idaho)  
2 713 
- South Bend Tribune 
(Indiana)  
2 541.5 
- The Augusta Chronicle 
(Georgia)  
2 578.5 
- The Patriot Ledger (Quincy, 
MA)   
2 467.5 
- The Times Union (Albany, 
NY) 
 2 615.5 
- Chattanooga Times Free 
Press (Tennessee) 
 4 693 
- Deseret News (Salt Lake 
City)  
 6 567.8 
1 USA TODAY 2,284,219 4 554.8 
3 The New York Times 1,077,256 6 919.3 
5 Daily News (New York) 703,137 2 427 
6 The New York Post 702,488 1 376 
7 The Washington Post 673,180 2 917.5 
9 The Houston Chronicle 494,131 1 1,112 
15 The Star-Ledger (Newark, 
New Jersey) 
345,130 4 522 
16 The Philadelphia Inquirer 334,150 1 784 
17 Plain Dealer (Cleveland, 
Ohio)  
330,280 2 496.5 
18 The Atlanta Journal and 
Constitution 
326,907 1 1,010 
19 Star Tribune (Minneapolis, 
MN)  
322, 362 1 1,994 
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Ranka Newspaper Daily 
Circulation 
Number of 
Xenical 
Articles  
Meanb 
Word 
Count 
20  St. Petersburg Times 
(Florida) 
316,007 2 462 
21 Chicago Sun-Times 312,274 2 414.5 
23 The Oregonian  304,399 1 987 
29 The Orange County 
Register 
250,724 2 713.5 
30 The Miami Herald 240,223 1 1,974 
31 San Jose Mercury News 
(California) 
234,772 1 766 
37 The Seattle Times 220,863 1 1,303 
42 Pittsburgh Post-Gazette 
(Pennsylvania)  
214,374 2 709.5 
47 Columbus Dispatch (Ohio) 199,524 1 982 
48 Saint Paul Pioneer Press 
(Minnesota) 
191,768 2 825.5 
53 Times-Picayune (New 
Orleans, LA) 
179,834 2 382 
55 Buffalo News (New York) 178,365 1 770 
60 Austin American-
Statesman (Texas) 
170,309 3 839.3 
64 The Record (Bergen 
County, NJ) 
163,329 4 1111 
68 Fresno Bee (California) 150,334 1 295 
71 Florida Times-Union 
(Jacksonville, FL) 
144,391 1 1,714 
74 Birmingham News 
(Alabama)  
140,438 1 632 
79 Seattle Post-Intelligencer 129,563 1 701 
97 Albuquerque Journal 
(New Mexico) 102,902 
1 1,336 
99 The Post and Courier 
(Charleston, SC) 100,400 
1 914 
aRank = rank within the List of the Top 100 Daily Newspapers from 
BurrellesLuce, Data reflects figures from the Audit Bureau of Circulation for the 
six-month period ending 3/31/08. “–“ indicates a newspaper that was not on the 
List of the Top 100 Daily Newspapers.  
bMean word count for Xenical article(s) from each newspaper. Data reflects word 
count from LexisNexis Academic, or calculated by averaging the word counts of 
multiple articles from a single newspaper.  
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Table 2 
Newspapers in the Sample of Alli Articles (n = 98) 
Ranka Newspaper Daily 
Circulation 
Number of 
Alli 
Articles  
Meanb 
Word 
Count 
- Chambersburg Public Opinion 
(Pennsylvania) 
 1 644 
- Chicago Daily Herald  1 930 
- Connecticut Post Online 
(Bridgeport, Connecticut) 
 1 632 
- Eureka Times-Standard 
(California) 
 1 516 
- Kalamazoo Gazette (Michigan)  1 254 
- Lancaster New Era 
(Pennsylvania) 
 1 864 
- Mobile Register (Alabama)  1 1218 
- Muskegon Chronicle 
(Michigan) 
 1 1013 
- Pasadena Star-News 
(California) 
 1 489 
- Patriot News (Harrisburg, 
Pennsylvania) 
 1 902 
- Riverfront Times (St. Louis, 
Missouri) 
 1 545 
- Saginaw News (Michigan)  1 584 
- San Gabriel Valley Tribune 
(California) 
 1 716 
- Sentinel & Enterprise 
(Fitchburg, Massachusetts) 
 1 871 
- The Augusta Chronicle 
(Georgia) 
 1 566 
- The Bismarck Tribune  1 778 
- The Capital (Annapolis, MD)  1 337 
- The New York Sun  1 570 
- The Washington Times  1 460 
- Whittier Daily News 
(California) 
 1 779 
- Chattanooga Times Free Press 
(Tennessee) 
 2 469 
- Deseret News (Salt Lake City)  2 511 
- Lincoln Journal Star (Nebraska)  2 840 
- Flint Journal (Michigan)  3 457.3 
- Pittsburgh Tribune Review  3 676.7 
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Ranka Newspaper Daily 
Circulation 
Number of 
Alli 
Articles  
Meanb 
Word 
Count 
- The Times Union (Albany, NY)   3 456 
- The State Journal-Register 
(Springfield, IL) 
 1 768 
1 USA Today 2,284,219 3 480.3 
3 The New York Times 1,077,256 3 808 
5 Daily News (New York) 703,137 4 581.3 
6 The New York Post 702,488 1 928 
7 The Washington Post 673,180 1 904 
8 Chicago Tribune 541,663 1 675 
9 The Houston Chronicle 494,131 2 712.5 
12 The San Francisco Chronicle 
(California) 
370,345 1 1018 
14 The Boston Globe 350,605 3 566.3 
15 The Star-Ledger (Newark, New 
Jersey) 
345,130 3 815 
18 The Atlanta Journal and 
Constitution 
326,907 2 780.5 
19 Star Tribune (Minneapolis, 
MN) 
322,362 1 1,064 
20 St. Petersburg Times (Florida) 316,007 1 1,292 
21 Chicago Sun-Times 312,274 3 561.3 
24 The San Diego Union-Tribune 288,669 2 997 
25 Sacramento Bee (California) 268,755 1 589 
27 St. Louis Post-Dispatch 
(Missouri) 
255,057 1 696 
37 The Seattle Times 220,863 1 901 
38 Tampa Tribune (Florida) 220,522 1 960 
39 South Florida Sun-Sentinel 
(Fort Lauderdale) 
218,286 2 875 
42 Pittsburgh Post-Gazette 
(Pennsylvania) 
214,374 2 535 
47 The Columbus Dispatch (Ohio) 199,524 1 813 
50 Contra Costa Times (California) 183,086 2 868.5 
52 Arkansas Democrat-Gazette 182,212 2 652 
55 Buffalo News (New York) 178,365 1 654 
57 Richmond Times-Dispatch 
(Virginia) 
175,265 3 620.3 
58 The Virginian-Pilot (Norfolk, 
VA) 
175,005 1 879 
62 Palm Beach Post (Florida) 164,474 1 649 
64 The Record (Bergen County, 
NJ) 
163,329 1 511 
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Ranka Newspaper Daily 
Circulation 
Number of 
Alli 
Articles  
Meanb 
Word 
Count 
74 Birmingham News (Alabama) 140,438 1 750 
76 The Providence Journal (Rhode 
Island) 
139,055 1 448 
78 The Daily News of Los Angeles 137,344 2 755.5 
89 Tulsa World (Oklahoma) 112,968 1 475 
92 The Post-Standard (Syracuse, 
New York) 
304,399 1 668 
96 The Philadelphia Daily News 107,269 1 677 
97 Albuquerque Journal (New 
Mexico) 
102,902 1 597 
aRank = rank within the List of the Top 100 Daily Newspapers from 
BurrellesLuce, Data reflects figures from the Audit Bureau of Circulation for the 
six-month period ending 3/31/08. “–“ indicates a newspaper that was not on the 
List of the Top 100 Daily Newspapers.  
bMean word count for Alli article(s) from each newspaper. Data reflects word 
count from LexisNexis Academic, or calculated by averaging the word counts of 
multiple articles from a single newspaper.  
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Table 3   
Frequency Data: Xenical    
Feature of the Weight Loss Drug Yes No 
Publication before the drug’s market release? 2.4% 97.6% 
Presence of a quote by a layperson?     27.1% 72.9% 
Presence of a quote by a physician?    35.3% 64.7% 
Presence of a quote by a dietitian?   9.4% 90.6% 
Presence of a quote by a scientist? 35.3% 64.7% 
Presence of a quote by a pharmacist? 1.2% 98.8% 
Presence of a quote by a psychotherapist? 3.5% 96.5% 
Presence of a quote by the drug’s manufacturer? 29.4% 70.6% 
Role of FDA in relation to drug mentioned?  76.5% 23.5% 
BMI standards for drug usage mentioned?  23.5% 76.5% 
Side effects of drug mentioned?  94.1% 5.9% 
Promise of weight loss mentioned?  77.6% 22.4% 
Mechanism of weight loss mentioned? 94.1% 5.9% 
Contraindications of drug mentioned?  29.4% 70.6% 
Recommendations for change in diet mentioned?  76.5% 23.5% 
Recommendations for change in physical activity 
mentioned?  
28.2% 71.8% 
Recommendations for counseling mentioned?  1.2% 98.8% 
Cost of drug mentioned?   45.9% 54.1% 
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Table 4   
Frequency Data: Alli   
Feature of the Weight Loss Drug Yes No 
Publication before the drug’s market release? 46.9% 53.1% 
Presence of a quote by a layperson?     33.7% 66.3% 
Presence of a quote by a physician?    27.6% 72.4% 
Presence of a quote by a dietitian?   19.4% 80.6% 
Presence of a quote by a scientist? 3.1% 96.9% 
Presence of a quote by a pharmacist? 13.3% 86.7% 
Presence of a quote by a psychotherapist? 1.0% 99.0% 
Presence of a quote by the drug’s manufacturer? 62.2% 37.8% 
Role of FDA in relation to drug mentioned?  81.6% 18.4% 
BMI standards for drug usage mentioned?  6.5% 93.9% 
Side effects of drug mentioned?  93.9% 6.5% 
Promise of weight loss mentioned?  75.5% 24.5% 
Mechanism of weight loss mentioned? 90.8% 9.2% 
Contraindications of drug mentioned?  31.6% 68.4% 
Recommendations for change in diet mentioned?  93.9% 6.1% 
Recommendations for change in physical activity 
mentioned?  
67.3% 32.7% 
Recommendations for counseling mentioned?  3.1% 96.9% 
Cost of drug mentioned?   46.9% 53.1% 
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Table 5 
Inter-rater Reliability Data: Pilot Test  
 
Variable      κ 
Duplicative 1.0 
Rank 1.0 
Page Number 1.0 
Word Count 1.0 
Month 1.0 
Date 1.0 
Year 1.0 
Day 0.926 
Drug Code  - a 
Publication before the drug’s market release? - 
Presence of a quote by a layperson?     1.0 
Presence of a quote by a physician?    0.828 
Presence of a quote by a dietitian?   - 
Presence of a quote by a scientist? 1.0 
Presence of a quote by a pharmacist? - 
Presence of a quote by a psychotherapist? 1.0 
Presence of a quote by the drug’s manufacturer? 1.0 
Role of FDA in relation to drug mentioned?  - 
BMI standards for drug usage mentioned?  1.0 
Side effects of drug mentioned?  1.0 
Promise of weight loss mentioned?  0.891 
Mechanism of weight loss mentioned? 1.0 
Contraindications of drug mentioned?  0.904 
Recommendations for change in diet mentioned?  0.904 
Recommendations for change in physical activity mentioned?  0.904 
Recommendations for counseling mentioned?  1.0 
Cost of drug mentioned?   - 
a = κ  could not be computed because both coders put the same response for  
each answer, which was appropriate.  
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CHAPTER 4 
DISCUSSION 
 In 2007, GlaxoSmithKline (GSK) spent $150 million on a multi-media 
marketing plan to promote sales of the new over-the-counter weight-loss drug Alli 
(60 mg orlistat) to the American public (Miley, 2009).  The prescription version, 
branded as Xenical (120 mg orlistat), had been approved by the FDA and sold 
since 1999.  Acting locally in the intestine, orlistat works by preventing the 
absorption of 25% to 30% of dietary fat.   
 Anticipation of success was high; the manufacturer expected annual sales 
of Alli to reach $150 billion (Ostrov and Molina, 2007). A February 2007 press 
release described the drug: “Approved for use by overweight adults in 
conjunction with a reduced-calorie, low-fat diet, Alli helps people lose 50 per cent 
more weight than with diet alone. Alli is the only FDA-approved weight-loss 
product available to consumers without a prescription, and it is the first clinically-
proven over-the-counter product to be combined with a comprehensive support 
program” (GSK, 2007a). A company spokesperson described Alli, pronounced 
“ally”, as being an “ally or partner helping you to lose weight” (Leonard, 2007).  
 The extensive marketing plan included traditional branded print 
advertising in newspapers and magazines, television commercials, and an 
impressive Internet presence. In addition to banner advertising and videos about 
Alli posted on websites, GSK created several websites, including MyAlli.com and 
AlliConnect.com, to offer online support to users and to market the drug to 
potential consumers.  The month before Alli became available, GSK built a multi-
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media interactive exhibit called the Alli Experience in New York City’s Union 
Square, a heavily traveled pedestrian zone, which was described in a press release 
as “a five-zoned sensory tour that leads to an interactive journey and multi-media 
education about weight loss realities” (GSK, 2007b). To reach consumers who 
were not able to visit the Alli Experience, a video tour of the exhibit was posted 
on the Internet (Alliupdates, 2011).   
 In addition, two books providing guidance on integrating Alli into a 
lifestyle modification plan were published. The Alli Diet Plan: Your Essential 
Guide to Success with alli, written by a physician who was also quoted in the 
GSK press release welcoming Alli. The other book was entitled Are You Losing 
It? Losing Weight Without Losing Your Mind: Weight Loss Experts Give You 
Insights, Answers and Encouragement.  The author of the other book was cited as 
an author of this book as well and described as an M.D. and the director of the 
Center for Nutrition and Weight Management at Boston Medical Center. The 
other authors were a PhD and director for the Center for Obesity Research and 
Education at Temple University, a professional chef, and another PhD and 
founder and director of the Weight Management Center at the University of 
Pittsburgh Medical Center.   
 Sales of Alli were high for the first few months, but declined quickly. The 
unwelcome side effects of flatulent diarrhea when dietary fat intake exceeded the 
recommended low amount at each meal and the monthly cost contributed to 
consumer’s eventual disillusionment with the product. Reports of severe liver 
injuries potentially associated with orlistat use began to surface and in 2009, the 
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FDA announced it was reviewing the safety of Alli and Xenical. In 2010, the 
FDA announced that both Alli and Xenical should carry warnings about possible 
liver damage, though technically there was no confirmed cause-effect relationship 
(FDA, 2010). Findings from a large clinical study in Canada in 2011 supported 
earlier associations found between orlistat and oxalate-induced acute kidney 
injuries in other clinical studies (Weir, 2011). Recently, GSK decided to stop 
selling Alli and offered the product line for sale to other drug manufacturers 
(Hirschler, 2011).  
 This study explored how newspapers framed both Xenical and Alli.  Based 
on this content analysis, GSK was shown to have used an aggressive marketing 
strategy exerted a powerful influence on the media production process, which 
extended to newspaper journalism treatment of Alli.   
 Newspaper articles about Xenical and Alli starting from three months 
prior to their FDA approval dates to one year after their market release date 
comprised the study sample. (Xenical was approved on Friday, April 23, 1999, 
and was available to be prescribed the following Monday, April 26, 1999. Alli’s 
approval date was February 27, 2007, and was available to the public four months 
later on June 14, 2007.) The difference in the time between FDA approval and 
market release was reflected in the production of articles about each weight-loss 
drug. While almost all of the Xenical articles were published after the market 
release date, about half of the Alli articles were published before the market 
release, reflecting the build-up of marketing efforts by the manufacturer.  People 
were “counting the days” until Alli was available in stores.   
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 Most of the Xenical articles in the sample were published in late April, 
right after the market release date, and May.  In contrast, the highest number of 
Alli articles was published in June 2007, which is understandable given the June 
14, 2007 market release date. February 2007 had the second-highest number of 
Alli articles published, reflecting an increase in article publication after the FDA 
approval date of February 27, 2007.  Media interest in Alli had fallen by the end 
of 2007, with very few articles being published in the first half of 2008.   
 To evaluate the frames utilized in the articles, the sources to which quotes 
were attributed were assessed. Seven possible sources were coded: the layperson, 
physician, dietitian, scientist, pharmacist, psychotherapist, and drug manufacturer.  
Quoting from a particular source emphasizes that source’s perspective in relation 
to the drug and transfers that source’s credibility, and the group represented by 
that source, to the information being presented in the article. For example, an 
article that attributes a quote praising a weight-loss drug to a physician elevates 
the drug’s status to being generally medically approved through the implication 
that this source is representative of the larger medical community.  
 Physicians and scientists were quoted in one-third of the articles about 
Xenical.  Since Xenical requires a prescription, it makes sense that medical and 
scientific authority figures were represented most often in the sample. The 
manufacturer and the layperson were the next most-commonly cited sources of 
information in less than one-third of the articles about Xenical.  
 For Alli, the top news source was the drug manufacturer, cited in nearly 
two-thirds of the sample. It is surprising that the manufacturer was given such a 
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powerful voice in the majority of the articles, even given its ambitious media 
campaign, especially when the other types of sources were consulted so 
infrequently by comparison.  The layperson was the next most common source, 
quoted in one-third of the sample. The scientific and medical communities were 
represented in a minority of the sample: Less than one-third attributed quotes to 
physicians, less than one-fifth quoted dietitians, and pharmacists, scientists, and 
psychotherapists were rarely mentioned.  
 The overreliance on the manufacturer as a news source is problematic 
because there is an inherent bias in the information provided to the journalist 
about the drug. Powers and Andsager (1999) studied media frames in newspaper 
coverage of the silicone breast implant controversy between women with implants 
who attributed serious health problems to the implants and the implant 
manufacturers. After a class action lawsuit was filed against Dow Corning and 
other implant manufacturers in 1994 and the court awarded a $4.25 billion 
settlement to 145,000 registrants, Dow Corning launched a major media campaign 
to restore its image. The media campaign focused on three major newspapers: the 
New York Times, Chicago Tribune, and Wall Street Journal.  The researchers 
used a coding scheme to examine news sources and to identify frames in articles 
published in those three newspapers between January 1992 and December 1996, 
dividing this time period into 1992-3 and 1994-96.  Results indicated that in 1992-
93, there was a focus on health risks as well as the actions of the implant 
manufacturer.  Later reporting in 1994-96 demonstrated a decrease in reporting on 
health risks as the actions of the manufacturer became the sole focus of coverage.  
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While the manufacturer was the most commonly cited news source in both time 
periods, reporting about the manufacturer was more sympathetic in the later time 
period.  News sources questioning the connection between the implants and health 
issues were more common in the later time period as well. The researchers 
concluded that the manufacturer’s media campaign influenced reporting on the 
silicone breast implant controversy, resulting in more favorable treatment in 
newspaper articles.  They caution that journalists should not rely too much on the 
manufacturers and their public relations staff who control health product 
information.   
 Depending too much on the manufacturer as a news source transforms a 
newspaper article into a cleverly disguised advertisement for the product. Hampl 
et al. (2006) wrote about the influence of direct-to-consumer (DTC) advertising of 
prescription medication on consumer behavior. Negative effects of DTC 
advertising include consumers’ developing unrealistic expectations of the drug 
and increased pressure on health care providers to prescribe drugs to less-than-
ideal candidates (Hampl et al., 2006).  While most consumers have some 
skepticism about DTC advertising (Hampl et al., 2006), most trust newspapers to 
publish fair, unbiased articles about drugs, along with other health issues.  The 
journalistic ideal of objectivity is eroded when reporters rely on drug 
manufacturer’s press releases, public relations personnel, and physicians and 
scientists who are associated with the manufacturer (e.g. through administering 
the clinical trials) to provide information about a product without also seeking out 
the opinions of other credible experts in the scientific and medical community 
 28 
who have opposing views.  The danger of encouraging the usage of an over-the-
counter product such as Alli is increased because any consumer can buy it without 
the guidance of a health care provider who can judge whether the drug is 
appropriate for the individual’s health condition, given the drug’s 
contraindications.   
 Layperson quotes, cited in one-third of the articles, frequently expressed 
excitement and positive sentiments about the drug.  This is not surprising, again, 
due to the manufacturer’s media campaign.  As in DTC advertisements that use 
actors similar in demographic characteristics such as sex, age, and race to the 
audience to model positive attitudes toward the drug and show the drug’s 
successful effects, attributing a positive quote about Alli from the layperson is an 
influential way of swaying public opinion in favor of Alli (Hampl et al., 2006).   
 Dietitians were represented much more often in relation to Alli than 
Xenical. Dietitians work in many settings, from clinical settings, in food service 
roles and community agencies, and are more accessible to journalists than 
doctors. Though dietitians have food, health, and nutrition expertise, they do not 
prescribe. It is likely that because a doctor’s prescription is not necessary to buy 
Alli, journalists considered a dietitian’s expertise to be sufficient.  
 Over three-quarters of the Xenical articles and slightly more than that for 
the Alli articles emphasize FDA approval status, which implies a guarantee of 
safety and effectiveness. Journalists rely on the government as a news source 
because it is perceived to be a credible authority on health information and is a 
relatively accessible source of information.  The increased frequency of the 
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mentions of FDA approval status in relation to Alli reflects the manufacturer’s 
branding of Alli as “the only FDA-approved weight-loss product available to 
consumers without a prescription” (GSK, 2007)  
 The majority of the reporting on both drugs neglected to mention BMI 
standards qualifying individuals as appropriate candidates for usage as well as the 
contraindications for use, e.g., pre-existing health conditions such as liver disease, 
pregnancy, eating disorders.  The under-reporting of these critical bits of 
information contributes to the perception that the drug is appropriate for anyone 
who wants to lose weight for cosmetic reasons and promotes ignorance of the 
drug’s health risks.  Given the connection between orlistat and the reports of 
severe liver and kidney injuries, one wonders how much the omission of critical 
information from newspapers affected those consumers’ decisions to use orlistat.  
  There were several similarities between how both drugs were 
characterized.  Both were, not surprisingly, mentioned as promising a certain 
quantity of weight loss and working best in accordance with dietary changes.  The 
mechanism by which each drug worked was often mentioned.  Counseling was 
rarely mentioned for both drugs.  Counseling information was specified as a 
variable because successful weight-loss strategies include changes in eating 
behavior and other lifestyle patterns, which counseling can help to support.   
 One key difference is that a recommendation for physical activity was 
more frequently mentioned in relation to Alli, which is sensible given the 
manufacturer’s marketing strategy to position Alli as an important component in 
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an overall program involving a low-fat diet, regular exercise, and use of the Alli 
Web site for online social support.  
 Another logical difference is that the drug’s cost was mentioned more 
often for Alli, makes sense given its OTC status and out-of-pocket cost. The 
monthly cost of Alli was $60-70 versus $100 for Xenical, which was covered by 
some insurance plans.  
 The findings in this study support the need for newspaper reporting that 
demonstrates scientific, including nutrition, knowledge when the topic is a 
weight-loss medication. Saguy and Almeling (2008) found through their content 
analysis of obesity frames in medical science media and mainstream news media 
that the journalists depended heavily on press releases for pre-packaged copy.  
They recommended that journalists seek skeptics in the medical and scientific 
community to offer opposing viewpoints in order to provide a well-rounded, 
unbiased perspective on issues. Moynihan et al. (2000) examined newspaper and 
television coverage of three prescription medications and found that news stories 
frequently provided inaccurate information about the drugs’ benefits, risks, and 
costs and neglected to report the financial conflicts of interests between drug 
manufacturers and experts or study groups.  The study found a need to improve 
the quality of medical reporting and suggested that journalists and editors use an 
evidence-based approach to medicine and focus their reporting on the magnitude 
of absolute and relative benefits of a drug, what groups of patients can benefit, the 
associated risks and costs, and the relationships between the sources of 
information about the medication (e.g., studies, experts) and the manufacturers 
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who will profit from the sales of the medication (Moynihan et al., 2000).  While 
journalists need training in reporting on health issues, health practitioners need 
training in how to work with journalists to promote public health. Campo and 
colleagues (2009), in their analysis of newspaper coverage of articles about 
college binge-drinking, found a need for health experts to use media advocacy to 
add public health issues to the media agenda.   
 In conclusion, the way that Alli was framed in newspapers reflected the 
manufacturer’s branding of it as a safe (implied by FDA-approval status), 
effective (implied by FDA-approval status) drug (requiring changes in diet and 
exercise) that was appropriate for everyone (due to the under-reporting of BMI 
standards and contraindications).  One limitation of this study was the availability 
of newspaper articles through the LexisNexis Academic database. Future research 
should include a content analysis of the portrayal of weight-loss drugs in other 
types of popular media, such as magazines.  It is important for nutrition 
professionals to gain insight into how the media influences behavior related to 
weight control.  
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Section 1 
History of FDA-Approved Weight-Loss Drugs 
 Developing a safe, effective, affordable weight-loss medication could have 
a significant impact on the global problem of obesity and overweight, which 
affects 1.1 billion individuals worldwide (Padwal et al., 2007). In the United 
States, two-thirds of adults are classified as overweight (body mass index [BMI] = 
25.0 – 29.9) or obese (BMI ≥ 30.0), as determined by weight (kg) divided by 
height squared (m2) (Centers for Disease Control and Prevention, 2009). The 
Brookings Institution estimated the total annual economic cost of obesity in the 
U.S. is $215 billion (Hammond and Levine, 2010). Excess weight is associated 
with increased risks of coronary heart disease, type 2 diabetes mellitus, 
hypertension, dyslipidemia, stroke, major depressive disorder, and other diseases 
(Centers for Disease Control and Prevention, 2009). 
 Research data demonstrates that weight loss has beneficial effects on high 
blood pressure in overweight and obese individuals with elevated blood pressure, 
normalizes blood lipids in overweight and obese individuals with dyslipidemia, 
and improves blood glucose levels in overweight and obese individuals with type 
2 diabetes (National Heart, Lung, and Blood Institute, 1998). Federal health 
authorities recommend an initial reduction of 10% of body weight over six 
months, then performing an assessment of health and weight status and setting 
additional weight loss targets afterwards as needed  (NHLBI, 1998). Even a 
reduction of 5 -10% in body weight is associated with improvements in 
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cardiovascular risk factors and reduced incidence of type 2 diabetes mellitus 
(Padwal, 2007).  
 Researchers noticed a significant increase in the prevalence of obesity and 
overweight in the United States starting in the late 1970s (Flegal et al., 2002). 
Data collection on obesity trends and their connection with chronic diseases 
became a public health priority.  Most researchers concluded that obesity was a 
chronic disease with genetic, behavioral, and environmental causes and that long-
term maintenance of weight loss, rather than short-term weight loss, was crucial 
for maintaining health (Heal, Gosden and Smith, 2009).  The prevailing belief that 
exercise, diet, and behavior modification alone are not considered sufficient long-
term treatment for obesity led to rekindled interest in drug therapy (Manson, 
1996).  
 For drug manufacturers, there is great market potential in identifying a 
successful weight-loss product. Marketdata Enterprises estimated that there were 
75 million individuals attempting to lose weight in the U.S. in 2010, with 80% of 
them trying to lose weight on their own and making four weight-loss attempts per 
year (PRWeb Health, 2011). The U.S. market for weight-loss medications, 
commercial weight-loss chains (e.g. Weight Watchers) meal replacements, diet-
food home delivery (e.g. NutriSystem), diet websites, and medically supervised 
weight-loss programs was valued at $60.9 billion in 2010 (PRWeb Health, 2011). 
In contrast, prescription weight-loss drugs in the U.S. represent just a fraction of 
the weight-loss market, with combined sales of only $154 million in 2009, 
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according to the most recent data available from IMS Health, a health care 
information company (Pollack, 2010a).  
 The weight-loss drug industry, however, has not fared well. In addition to 
generating low sales of existing products, manufacturers have not been successful 
at introducing new ones because they have not been able to earn regulatory 
approval.  There have been no approvals granted for new weight-loss drugs in the 
past twelve years since the 1999 approval of orlistat, a gastrointestinal lipase 
inhibitor that is available both by prescription (Xenical, 120 mg, manufacturer: 
Roche) and over-the-counter (Alli, 60 mg, manufacturer: GlaxoSmithKline). 
 The Food and Drug Administration (FDA) of the United States is the 
regulatory agency that evaluates and approves new drugs prior to their entry into 
the marketplace. Like all other types of medications, drugs designed to treat 
obesity must undergo extensive scrutiny to be eligible for approval by the FDA. 
The FDA, however, must balance its duty to evaluate efficacy and safety with its 
obligation not to block or delay access to new drugs that could potentially 
improve the health of many people (Schweitzer, 1997).   
 In September 2010, Lorqess (lorcaserin hydrochloride, manufactured by 
Arena Pharmaceuticals) failed to gain FDA approval because high doses of the 
drug caused tumor development in rats (Pollack, 2010b). The FDA defined 
Lorqess’s weight loss benefit for humans, as demonstrated in clinical studies, as 
“marginal” and requested further research on the carcinogenic potential of the 
drug (Pollack, 2010b). In October 2010, the FDA rejected Qnexa, manufactured 
by Vivus, despite its effectiveness at causing weight loss of 10.6% of initial body 
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weight after one year, compared with 1.7% initial body weight lost with placebo 
after one year (Pollack, 2010a). The concern about Qnexa, a blend of 
phentermine, a weight-loss drug approved for short-term use, and topiramate, an 
epilepsy and migraine medication known as Topamax and sold by Johnson & 
Johnson, was the long-term safety for pregnant individuals and individuals with 
heart problems (Pollack, 2010a). The FDA requested additional evaluations of 
safety for these populations.  In February 2011, the FDA refused to grant approval 
of Orexigen Therapeutic’s drug Contrave over concern about cardiovascular 
damage; the FDA demanded that the manufacturer conduct a large, long-term 
clinical trial to ensure that there would be no elevated risk of heart problems from 
using Contrave (Pollack, 2011).  
 The FDA’s caution regarding new weight-loss drugs stemmed in part from 
the postmarket research findings about Meridia (sibutramine, manufacturer: 
Abbott Laboratories), a prescription weight-loss drug that modulates the reuptake 
of the neurotransmitters noradrenaline and serotonin (Wirth, 2001).  Researchers 
conducting the Sibutramine in Cardiovascular Outcomes (SCOUT) trial, which 
lasted over five years and included over 10,000 individuals in Europe, Latin 
America, and Australia, found an association between Meridia and increased risks 
of heart attack and stroke in users with pre-existing heart disease, which is 
frequently asymptomatic. In October 2010, the FDA asked Abbott to stop selling 
Meridia.  
 The most widely used prescription-strength weight-loss drugs of the past 
two decades have been fen-phen, dexfenfluramine, Meridia, and Xenical.  Fen-
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phen was a combination of fenfluramine and phentermine, both of which had 
FDA-approval for short-term use.  During fen-phen’s heyday in the mid-1990s, 
many physicians considered these two drugs to have a symbiotic relationship for 
weight loss and began prescribing them “off label” as a duo, even though the 
combined use of these drugs had never been vetted by the FDA (Colman, 2005).  
In 1997, fenfluramine, half of fen-phen, was withdrawn from the market after 
reports of cardiovascular and pulmonary damage.  Dexfenfluramine, another 
appetite suppressant, was recalled at the same time as fenfluramine due to similar 
adverse reports.   
 As of June 2011, the only weight-loss drug available for long-term use in 
the U.S. is orlistat. In 2010, U.S. regulators decided that Alli, the over-the-counter 
form of orlistat, should carry warnings about potential liver injuries, though a 
cause-and-effect relationship had not been established at the time (Food and Drug 
Administration, 2010). In April 2011, GlaxoSmithKline announced it would sell 
off the Alli product line, among other drug products, less than four years after it 
was launched in June 2007 (GlaxoSmithKline, 2011).  
U.S. Food and Drug Administration (FDA) 
 The FDA’s regulatory role began with its creation as a federal agency in 
1938; according to the Federal Food, Drug, and Cosmetic Act, the FDA required 
manufacturers to submit evidence of a new drug’s safety before making the drug 
available for sale (Colman, 2005). Several amphetamine and amphetamine-like 
appetite suppressants, such as phentermine, were approved at this time.  In 1962, 
in the wake of the thalidomide tragedy in Europe in which the morning-sickness 
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drug thalidomide was found to be the cause of many severe birth defects when 
taken in early pregnancy (Schweitzer, 1997), the law was amended to require that 
manufacturers provide evidence of a drug’s safety and efficacy, obtained through 
long-term, well-controlled clinical trials. The FDA asked the National Research 
Council of the National Academy of Sciences to review almost 3,000 previously 
approved drugs. Without evidence of efficacy obtained through long-term clinical 
studies, however, the appetite suppressants were in danger of being removed from 
the market. Ultimately, the FDA agreed to allow them to remain on the market, 
but they were to be prescribed only for short-term use (a few weeks), which 
limited their usefulness, and they carried labels that warned against addiction. 
These two factors contributed to their gradual decline in popularity throughout the 
1970s and 1980s.  The introduction of fen-phen in the mid-1990s ended the 
demand for appetite suppressants (Colman, 2005).  
 Another popular FDA-approved weight-loss drug was 
phenylpropanalomine (PPA), a common ingredient in over-the-counter and 
prescription cold and sinus medications and over-the-counter weight loss products 
(FDA, 2005).  PPA reduced food intake in studies on animals, and produced 
vasoconstriction in humans (Bray, 2008).  PPA-based weight loss pills, such as 
Dexatrim, were available until 2000, when the FDA removed all medications 
containing PPA (including the decongestants) from the market because of reports 
that linked them to an increased risk of hemorraghic stroke (Ahmad, 2008).   
 The pre-market FDA approval process for a new weight-loss drug is 
expensive and time-consuming.  Before any research can be performed using 
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human subjects, toxicological and safety testing must be done on animals.  The 
drug company files an Investigational New Drug (IND) application with the FDA 
and must obtain IND approval before beginning any testing on humans 
(Schweitzer, 1997).  
 There are three phases of clinical development: phase I studies use small 
groups (<100) of healthy subjects to investigate the safety and metabolism of the 
drug, phase II studies use multiple dose amounts and larger groups of subjects 
(several hundred) to explore short-term side effects and risks of the drug, and 
phase III studies are larger (several hundred to several thousand individuals), with 
trials held at hospital and outpatient settings using the dose and route of 
administration that will be marketed (Schweitzer, 1997). Most phase II and III 
clinical trials are randomized, double-blind, and placebo-controlled (Schweitzer, 
1997).  In phases I and II, overweight and obese subjects with a broad range of 
BMIs (27 kg/m2  to 35 kg/m2) are treated to study how adiposity may affect the 
pharmokinetics of a drug (FDA, 2007).  In accordance with national guidelines on 
eligibility for pharmacotherapy for obesity (NHLBI, 1998), study participants are 
individuals with a BMI of at least 27 kg/m2 (with co-morbidities (e.g. type 2 
diabetes mellitus, hypertension, cardiovascular disease) or of at least 30 kg/m2 
(co-morbidities optional) (FDA, 2007).  
 After the completion of clinical testing, the drug company files a New 
Drug Application (NDA) containing all of the evidence from the clinical trials 
with the FDA; the FDA has 180 days to review the NDA, but can take more time 
depending on the amendments that need to be made to the NDA. In reality, 
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therefore, the FDA may take much more time to complete the review.  In 2002, 
the average FDA review time for the 26 drugs approved that year was 17.8 
months (Schweitzer, 1997). 
 The FDA has drafted guidelines for regulatory criteria of safety and 
efficacy for weight-loss drugs. According to the draft, the safety of a weight-loss 
drug can be determined in a study of 3,000 subjects randomized to active doses 
and 1,500 subjects randomized to placebo for one year of treatment (FDA, 2007).  
In reality, it is nearly impossible to predict the adverse event profile of a new drug 
due to the small sample size, the short duration of the trial, and the limited 
generalizability of the study population which typically excludes pregnant 
women, the elderly, individuals with multiple diseases, and individuals who are 
taking other medications that may interact with the drug being studied (Ahmad, 
2003). Due to the increased risks of cardiac valvulopathy presented by fen-phen 
and dexfenfluramine in the past, the FDA looks for adverse effects on cardiac 
function when assessing a new drug’s safety (Heal et al., 2009).  The primary 
efficacy endpoint is a difference in mean weight loss between the intervention and 
placebo groups of at least 5%; this difference must also be statistically significant 
(Heal et al., 2009).  In addition to weight reduction, which alone may provide 
only cosmetic and not medical benefits, the FDA requires improvements in 
obesity-related risk factors such as blood pressure, pulse,blood lipids, and (in 
individuals who have diabetes) glucose, insulin, and HbA1c) (FDA, 2007).  
 In addition to overseeing drug approvals, the FDA is responsible for 
monitoring the post-market safety of drugs through its Adverse Event Reporting 
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System (AERS).  Reports are submitted either from pharmaceutical companies, 
who receive information mainly from physicians and pharmacists, or from 
physicians, pharmacists , nurses, and other healthcare practitioners (Ahmad, 
2003).  
 Dietary supplements fall into a different category for the FDA.  The 
Dietary Supplement Health and Education Act of 1994 (DSHEA) released the 
FDA from the pre-market approval process of regulating dietary supplements, 
including those intended for weight loss (FDA, 1994).  Instead, DSHEA granted 
manufacturers the freedom to decide if a product was safe enough to market.  In 
contrast with the extensive process required for drug approval, there are no safety 
or efficacy standards in place for dietary supplements.   
Fen-phen 
 The first weight-loss drug to gain popularity in the 1990s was fen-phen, a 
combination of two appetite suppressants.  Fenfluramine, approved in 1973, was 
manufactured and sold under the brand name Pondimin by American Home 
Products (FDA, 1997).  Phentermine had been approved in 1959 and marketed 
under a variety of brand names, such as Fastin, Obephen, and Phentride (NIH, 
2010). The combined use of fenfluramine and phentermine, however, was never 
FDA-approved yet physicians prescribed the drugs separately – but to be taken 
together – as an increasing number of consumers demanded a medical weight-loss 
intervention.  Fen-phen became popular in the mid-1990s after the mass media 
publicized results from a small 1992 study that seemed to support fen-phen’s 
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effectiveness as a weight-loss drug (Colman, 2005). In 1996, physicians issued 18 
million “off-label” prescriptions for fen-phen (Connolly, 1997). 
 Both fenfluramine and phentermine suppress the appetite, though by 
different pathways in the hypothalamus. Fenfluramine binds with the serotonin 
reuptake pump, which inhibits reuptake and increases levels of the 
neurotransmitter serotonin circulating in the brain, which produces a feeling of 
fullness and decreases the appetite (PharmGKB, 2011a).  Phentermine, an 
amphetamine, stimulates the production and maintains high levels of 
catecholamines, a type of neurotransmitters, (e.g. norepinephrine) that block 
hunger signals and suppress the appetite (PharmGKB, 2011b).  Both drugs share 
similar adverse effects, such as anxiety, insomnia, tachyarrhythmia, hypertension, 
restlessness, dizziness, tremor, headache, dry mouth, unpleasant taste, nausea, 
vomiting, diarrhea, and/or constipation (Moyers, 2005).   
 Prior to fen-phen’s rise in popularity, there was scant scientific research to 
support its efficacy and safety.  There was one study, published in 1984, in which 
81 obese subjects were divided into four groups and treated for 16 weeks with 
either fenfluramine alone, phentermine alone, a combination of fenfluramine and 
phentermine (fen-phen), and a placebo (Weintraub, 1984). All of the participants 
were between the ages of 18 and 55 and body weights ranged from 30% to 80% 
above ideal body weight.  They followed a calorie-restricted diet and a behavior 
modification program, and exercised regularly in addition to taking the 
medication. Using a double-blind, parallel-control design, researchers found that 
the group that received fen-phen achieved weight loss (10.1% of initial body 
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weight) equivalent to those who received the individual drugs (phentermine: 
11.0% and fenfluramine: 8.4%) and significantly greater than that of those who 
received the placebo only (4.9%) (Weintraub, 1984). The phentermine group and 
the fenfluramine group experienced more cardiovascular side effects (e.g. 
palpitations) and central nervous system  (CNS) side effects (e.g. sleep 
difficulties, nervousness, depression, fatigue, and increased dreaming) than the 
placebo group. Because researchers found that the group taking fen-phen 
experienced fewer cardiovascular and CNS side effects than the phentermine 
group, and because there was no significant difference between the fen-phen 
group and the placebo group in relation to these side effects, they concluded that 
fen-phen’s seemingly reduced side effects made this drug combination a better 
choice than prescribing fenfluramine or phentermine individually. There was no 
significant difference in side effects between the fen-phen group and the 
fenfluramine group, however.  The dropout rate was high, however; only 45 out 
of 81 subjects completed the 16-week trial.  The 36 dropouts were distributed 
among the groups somewhat evenly; the fen-phen group had 8 out of 21 dropouts, 
the fenfluramine group had 10 out of 20 dropouts, the phentermine group had 8 
out of 20 dropouts, and the placebo group had 10 out of 20 dropouts.  Their 
reasons were almost evenly divided between drug-related causes and non-drug-
related causes (Weintraub, 1984). The researchers followed up on the same small 
study population for a total period of four years. Subjects were treated with 
varying doses of fenfluramine and phentermine to determine how to compound 
these drugs so their greatest weight-loss properties could be achieved (Weintraub, 
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1992).  During weeks 190 to 210, the medication was stopped, though the 
exercise, diet, and behavior modifications continued, and the lost weight was 
regained, demonstrating that fen-phen did not help with weight maintenance after 
its usage ended (Weintraub, 1992).  
 Because the FDA’s steps to determine drug safety were not followed for 
fen-phen – not to mention the FDA’s approval of “off label” use of medications – 
fen-phen’s drug combination had never been formally and rigorously tested for 
adverse effects before being prescribed.  Long-term use of fenfluramine and fen-
phen were associated with heart and lung damage, ultimately leading to the 
withdrawal of fenfluramine from the market due to data showing the drug 
increased the risk of potentially fatal pulmonary hypertension (Abenhaim, 1996 
and McMurray,1985).  In 1997, researchers at the Mayo Clinic reported they had 
conducted case reports on 24 subjects, none of whom had a history of cardiac 
disease, and found that fen-phen increased the risk of valvular heart disease.  All 
24 subjects were found to have damaged heart valves and eight had developed 
pulmonary hypertension (Connolly 1997).  The FDA issued a warning against 
fen-phen in response to these findings.  After receiving 75 reports of cardiac 
valvular damage after fen-phen use, the FDA issued a second warning about fen-
phen.  Finally, in September 1997, the FDA recalled fenfluramine after physicians 
reported that 30% of patients taking fen-phen had abnormal echocardiograms 
(FDA, 1997).  Adverse events were reported with fenfluramine usage whether 
phentermine was combined with it or not; therefore, fenfluramine was identified 
as the drug responsible for causing the cardiac valvulopathy (FDA, 1997).  Fen-
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phen’s legacy to subsequent weight-loss drugs in the U.S. was the stigma of 
danger, as well as the attraction of rapid and dramatic weight loss.  Though 
phentermine is still approved for short-term weight loss, demand is low; sales of 
phentermine in 2009 were just $36.5 million (Medical News Today, 2010).  
Dexfenfluramine 
  Marketed as Redux by Wyeth-Ayerst Laboratories, dexfenfluramine was 
approved by the FDA for short-term use for weight loss in 1996.  Redux 
generated sales of $206 million from July 1996 to July 1997 (Gerlin, 1997). It was 
recalled along with fenfluramine due to reports of cardiovascular and pulmonary 
damage in users (Kolata, 1997).  A selective serotonin reuptake inhibitor 
(Swinburn, 1996), dexfenfluramine is the dextro-stereoisomer of fenfluramine 
(Lafreniere, 1992) and is as efficacious as fenfluramine but at half the dose (30 
mg vs. 60 mg)  (Guy-Grand, Crepaldi, LeFebvre, Appelbaum, Gries and Turner, 
1989).  Side effects include tiredness, diarrhea, dry mouth, polyuria, and 
drowsiness (Guy-Grand et al., 1989).   
 Results of clinical studies support dexfenfluramine’s efficacy for up to six 
months. In a double-blind, placebo-controlled trial on 84 obese subjects on a 
reduced-fat, ad libitum diet, after 12 weeks, the treatment group had lost 
significantly more body weight and body fat (particularly in the abdominal 
region) as compared to the placebo group.  Blood lipid levels among individuals 
who took dexfenfluramine were significantly lower than their peers’, thereby 
reducing cardiovascular risk factors for those who took the medication (Swinburn, 
1996).  In a randomized, double-blind, placebo-controlled, multi-center study on 
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822 obese subjects, Guy-Grand and colleagues (Guy-Grand et al., 1989) 
examined the efficacy of dexfenfluramine, combined with energy restriction, in 
enhancing weight loss over a one-year period of active treatment. The researchers 
showed that mean weight loss was significantly greater in the treatment group 
than the placebo group at the six-month mark and after one year, when the mean 
weight loss in the treatment group was 9.82 kg and the mean weight loss in the 
placebo group was 7.15 kg .  Almost all of the weight loss in both groups 
occurred during the first six months of treatment.  The greater amount of weight 
regain in the placebo group during the second six months suggested that 
dexfenfluramine prevented weight regain in the treatment group, though it did not 
continue the weight reduction process after the plateau was reached at six months 
(Guy-Grand et al., 1989).   
 Another randomized, placebo-controlled study by Andersen and 
colleagues showed a significant difference in weight loss between the active 
treatment group and the placebo group at six months, but not after 12 months, 
indicating the plateau effect (Andersen, 1992).  Long-term studies (≥ 6 months) 
did not support continuing benefits of dexfenfluramine.  Pfohl and colleagues 
(1993) conducted a follow-up study three years later with research participants 
who had been treated with dexfenfluramine for a one-year period and found that 
the results of dexfenfluramine in the long term were comparable to those of 
behavior therapy alone (Pfohl, Luft, Blomberg and Schmulling, 1993).  Any 
benefit from its continuous long-term administration as an adjunct therapy to 
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other weight-loss interventions did not outweigh its potential cardiovascular and 
pulmonary risks.  
Sibutramine (Meridia®)  
 Branded as Meridia® by Abbott Laboratories, sibutramine was a 
prescription weight-loss drug that was approved for long-term use by the FDA in 
November 1997, the same year that fenfluramine and dexfenfluramine were 
recalled.  Meridia was available in the United States for nearly 13 years, till 
October 8, 2010, when the FDA asked Abbott to voluntarily recall the drug due to 
evidence that the drug was associated with a 16% elevated risk of adverse 
cardiovascular events.  Abbott immediately complied with the FDA’s request.   
 Till then, over 3 million prescriptions were filled between 2002 and 2010 
(Reuters, 2010).  Meridia modulates hunger and causes early satiety (Wadden, 
2005).  By inhibiting the reuptake of both serotonin and noradrenaline, Meridia 
had the potential for greater efficacy than dexfenfluramine, which acts only on 
serotonergic mechanisms, and phentermine, which acts only on noradrenergic 
mechanisms (Lean, 1997).  
 In the U.S., FDA approval was based on the results of clinical studies that 
demonstrated that approximately 60% of subjects who were treated with Meridia 
compared to 30% of subjects who received the placebo lost greater than 5% of 
their baseline body weight (FDA, 2010).  For example, in a randomized one-year 
trial of 224 obese subjects who received lifestyle-modification counseling, the 
daily use of 15 mg sibutramine doubled the amount of weight lost in overweight 
subjects and increased the number of subjects who achieved 5 – 10% weight loss 
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by three to four times compared to placebo and the same counseling (Wadden, 
2005).  Three doses – 5 mg, 10 mg, and 15 mg - were approved by the FDA 
(FDA, 2010).  The typical daily dosage of sibutramine was 10 mg to start, with a 
recommendation to increase to 15 mg in four weeks if weight loss was not 
sufficient.  Common side effects found during the clinical studies included an 
increased heartbeat, increased blood pressure, palpitations, headache, anxiety, 
dizziness, dry mouth, anorexia, insomnia, constipation, and headache (FDA, 
2010).   
 In European Union countries, Meridia was approved in 1999 only under 
the condition that the manufacturer was required to conduct a long-term, post-
market clinical trial to examine the effects of sibutramine on cardiovascular 
health.  Concerns came from the side effects of the increases in heartbeat and 
blood pressure that were noted in the pre-approval clinical trials.  
 In October 2010, the FDA requested that Meridia be withdrawn from the 
market. The randomized, double-blind, placebo-controlled trial that had been 
required by European regulatory authorities was called Sibutramine in 
Cardiovascular Outcomes (SCOUT).  Between 2003 and 2009, approximately 
10,000 overweight or obese subjects in Europe, Latin America, and Australia 
participated in SCOUT.  They had either a history of cardiovascular disease 
and/or type 2 diabetes mellitus plus at least one cardiovascular risk factor, e.g. 
hypertension, dyslipidemia, smoking, or diabetic nephropathy (James, 2010).  The 
results of SCOUT showed that the long-term use of sibutramine increased the risk 
of primary cardiovascular events (e.g., non-fatal myocardial infarction and stroke, 
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cardiovascular death) in patients with pre-existing cardiovascular disease by 16%  
(James, 2010) while the difference in weight loss between the treatment group 
and the placebo was a modest 2.5% (FDA, 2010).  The benefit of slightly 
increased weight loss was not enough to justify the increased cardiovascular risk.   
Orlista (Xenical and Alli®)  
 On April 23, 1999, the FDA approved orlistat, branded Xenical® in the 
United States by manufacturer Hoffman-La Roche,  as a prescription weight-loss 
drug for overweight adults with a BMI of at least 30, or 27 with at least one 
obesity-related risk factor (FDA, 2011).  Canada and many countries in Europe, 
South America, and Southeast Asia/Pacific approved orlistat as well (Lucas, 
2001).  The safety and efficacy of orlistat was established in many long-term 
clinical studies prior to its approval.  As a gastrointestinal lipase inhibitor, orlistat 
does not act upon appetite or satiety controls but rather locally in the small 
intestine, where it is minimally (< 2%) absorbed (Schwartz, 2008).  Unlike earlier 
weight-loss drugs such as fen-phen, Redux, and Meridia, orlistat was not 
associated with increased cardiovascular risks.   
 Orlistat works by binding to pancreatic lipase in the small intestine, 
decreasing the hydrolysis and absorption of dietary triglycerides (Schwartz, 
2008).  The standard prescription dosage of 120 mg three times daily prevents 
approximately 30% of dietary fat from being digested, which creates an energy 
deficit that leads to weight loss (Lucas, 2001) and undigested fat is excreted in 
feces.  Orlistat is meant to be used in conjunction with a reduced-calorie, low-fat 
diet as well as a regular exercise program.  The inhibition of lipid digestion 
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decreases the absorption of fat-soluble vitamins, so a multivitamin supplement is 
recommended to ensure against vitamin deficiencies when taking orlistat (Lucas, 
2001).  Excessive intake of dietary fat can lead to uncontrollable excretion of 
undigested dietary fat, which causes diarrhea and anal leakage, referred to as 
“treatment effects” by Hoffman-La Roche.  This unpleasant consequence is a 
form of aversion therapy since it discourages the individual from choosing to eat 
foods high in fat (Lucas, 2001).  
 Orlistat sales were $146 million in the first seven months of post-market 
release (Goetzl, 2000) but then declined quickly afterward and stayed low.  In 
2009, U.S. sales of Xenical were just 34 million Swiss francs (approximately 
$34.4 million U.S. dollars)  (Roche, 2010).  The timing of Xenical’s 1999 
introduction to the U.S. market was unfortunate; consumers and physicians were 
skittish to try a new weight-loss drug in the wake of the 1997 recall of fen-phen 
(Thomaselli, 2007).  Consumers were not as impressed by the relatively modest 
weight loss caused by Xenical as opposed to the rapid weight loss caused by fen-
phen  (Morrow, 1999).  The unpleasant side effect of fecal incontinence was also 
responsible for Xenical’s low popularity. The cost of a one-month supply of 
Xenical in 2006 was about $100 and was not covered by most insurance plans 
(Saul, 2006).  
 In the following research studies, orlistat therapy was found to be effective 
for weight loss and weight maintenance in obese and overweight adults.  Orlistat 
was well-tolerated by subjects, the gastrointestinal side effects did not often cause 
many subjects to withdraw, and the theoretical possibility of deficiencies in fat-
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soluble vitamins resulting from orlistat use occurred infrequently.  In these 
studies, a placebo run-in phase was used to assess the effects of any diet, physical 
activity, and lifestyle modifications separately from the effects of the drug 
treatment.   
 Davidson and colleagues (1999) conducted a two-year, randomized, 
double-blind, placebo-controlled trial on obese adults (BMI range: 30 – 43 kg/m2) 
and found that subjects treated with orlistat (either 60 mg or 120 mg) lost 
significantly more weight (8.76 ± 0.37 kg) than subjects who received the placebo 
(5.81 ± 0.67 kg) after the first year (Davidson and colleagues’ names here, 1999).  
Orlistat treatment demonstrated efficacy for weight maintenance in the second 
year as well.  The subjects who received 120 mg orlistat had significantly less 
weight regain (3.2 ± 0.45 kg, 35% regain) than those who had received 60 mg 
orlistat (4.26 ± 0.57 kg, 51.3% regain) or placebo (5.63 ± 0.42 kg, 63.4% regain).  
Treatment with 120 mg orlistat after two years was associated with a greater 
decrease in mean waist circumference compared to placebo (-4.52 ± 0.8 cm for 
orlistat group vs. -2.38 ± 1.0 cm for placebo, P < 0.05), as well as with 
improvements in fasting low-density lipoprotein cholesterol and insulin levels.  
Treatment with 120 mg orlistat after one year was associated with a greater 
decrease in systolic blood pressure in the treatment group (119.4 ± 0.5 to 118.6 ± 
0.6 mm Hg) than in the placebo group (118.6 ± 0.9 to 119.6 ± 1.3 mm Hg), P = 
0.002).  The 120 mg dose of orlistat showed greater benefits than the 60 mg 
orlistat, but both were significantly more effective for weight loss, weight 
maintenance, and improving cardiovascular risk factors than placebo.  
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 Another two-year, multi-center, randomized, double-blind, placebo-
controlled study with 783 overweight or obese subjects (BMI range: 28 – 43 
kg/m2) by Rossner and colleagues (2000) demonstrated similar results.  Two 
doses of orlistat were tested, 60 mg and 120 mg.  After two years, weight loss was 
significantly (P < 0.001) higher for the 120 mg orlistat group (9.7%) and the 60 
mg orlistat group (8.6%) than the placebo group (6.6%).  After one year of 
treatment, 38.3%  (P < 0.001) of subjects in the 120 mg orlistat group and 31.2%  
(P = 0.002) of subjects in the 60 mg orlistat group had lost > 10% of their body 
weight, compared to 18.8% of subjects who had received the placebo (P < 0.001).  
Additionally, significantly more individuals in the orlistat groups lost > 5% of 
their body weight after both the first and second years of treatment than subjects 
who had received the placebo (P < 0.001).  Orlistat users had significantly less 
weight regain compared to placebo users too.  Weight loss > 10% was maintained 
by a greater proportion of 120 mg and 60 mg orlistat recipients (28.2% and 
29.0%, respectively) than placebo recipients (18.6%) after two years.  Orlistat 
users also had a greater decrease in waist circumference (6.2 cm and 6.0 cm in the 
120 and 60 mg orlistat groups, respectively) than placebo users (4.7 cm) after one 
year.  Orlistat users had significantly improved lipid profiles as well (Rossner, 
2000). Only 6% of subjects withdrew from the study due to adverse effects of the 
drug treatment; overall, orlistat was well-tolerated.  No clinical symptoms of 
vitamin deficiencies were noted, and serum levels of fat-soluble vitamins stayed 
within normal ranges, though levels of vitamins D (25-OH vitamin D) and E, and 
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β-carotene were significantly lower in the orlistat groups than in the placebo 
group.   
 Hauptman and colleagues (2000) found similar benefits to orlistat in a 
two-year, randomized, double-blind, placebo-controlled, multi-center study with 
635 obese (BMI range: 30 – 44 kg/m2) subjects in primary-care settings where 
some dietary guidance was provided during the lead-in phase (Hauptman, Lucas, 
Boldrin, Collins, and Segal, 2000).  Weight loss after one year was significantly 
higher for subjects in both the 120 mg orlistat (7.94 ± 0.57 kg) and 60 mg orlistat 
(7.08 ±0.54 kg) groups than for subjects in the placebo group (4.14 ± 0.56 kg).  
Proportionately more subjects in the 120 mg group (50.5%) and the 60 mg group 
(48.8%) lost > 5% of their starting body weight compared to placebo users 
(30.7%; P < 0.001).  Significantly more orlistat recipients (34%, P < 0.001) 
maintained a weight loss of  ≥ 5 % after the second year of the study as well 
compared to 24% of the placebo users.  Serum lipid profiles and blood pressure 
markers showed greater improvements in orlistat users relative to placebo users.  
Orlistat was well-tolerated by subjects.   
 The benefits of orlistat treatment for obese individuals with type 2 
diabetes heavily outweigh the side effects.  Hollander and colleagues (1998) 
conducted a one-year, randomized, double-blind study that demonstrated orlistat’s 
benefits to overweight and obese (BMI range: 28 – 40 kg/m2) adults with type 2 
diabetes who were taking oral sulfonylureas as prescribed (Hollander, Elbein, 
Hirsch, Kelley, McGill, Taylor, Weiss, Crockett, Kaplan, Comstock, Lucas, 
Lodwick, Canovatchel, Chung, and Hauptman, 1998).  Subjects received either 
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120 mg orlistat (n = 163) or placebo (n = 159) and an energy-controlled diet.  
After one year, mean weight loss was significantly greater in the orlistat group 
(6.2 ± 0.45 kg) than in the placebo group (4.3 ±0.49 kg) (P <0.0001).  Twice as 
many subjects in the orlistat group (49%) than in the placebo group (23%) lost ≥ 
5% of initial body weight (P < 0.0001).  Orlistat treatment was associated with 
significant improvement in glycemic control, as evidenced by decreases in HbA1c 
(P < 0.0001) and fasting plasma glucose (P < 0.0001) and reductions in the 
dosages of oral sulfonylurea medications (P < 0.0001).  The orlistat group also 
had significantly greater improvements in lipid parameters: greater reductions in 
total cholesterol (P < 0.0001), LDL cholesterol (P < 0.0001), triglycerides (P < 
0.05), and LDL-to-HDL cholesterol ratio (P < 0.0001).  Orlistat was well-
tolerated overall; the gastrointestinal side effects of excessive dietary fat intake 
were mild to moderate and were not often associated with withdrawal from the 
study.  Seven of the participants in the treatment group dropped out of the study 
due to gastrointestinal events while two participants in the placebo group dropped 
out for the same reason.  In the orlistat group, 85% of the initial 163 subjects 
completed the study, compared with 73% of the initial 159 subjects in the placebo 
group. Fat-soluble vitamin levels remained within the normal ranges, and vitamin 
supplementation was required for only a few subjects.  
 Reinforcing earlier studies on animals that showed that dietary 
composition influences insulin sensitivity independently of body weight, a study 
treating a sample of 47 obese (BMI range: 32.1 ± 0.4 kg/m2) female subjects with 
orlistat vs. placebo demonstrated that reducing dietary fat intake through 
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decreased absorption had beneficial effects on insulin resistance, as well as on 
body fat composition. Tiikkainen and colleagues (2004) administered a 
hypocaloric diet and either 120 mg orlistat three times daily (for a daily total of 
360 mg orlistat) or placebo (Tiikkainen, Bergholm, Rissanen, Aro, Saminen, 
Tamminen, Taramo, and Yki-Jarvinen, 2004).  At baseline, the two groups had 
similar ages, weights, BMIs, waist-to-hip ratios, body fat composition, insulin 
sensitivity, and dietary intakes regarding macronutrient composition and alcohol 
and fiber intake. The goal was to induce a moderate amount (8%) of weight loss 
over 3 to 6 months in both groups and compare the effects on markers of insulin 
sensitivity, on serum fatty acid composition, and on body fat composition.   
 The researchers measured whole-body insulin sensitivity (M-value) and 
serum fatty acids using the euglycemic insulin clamp technique, which simulates 
glucose uptake by the body’s tissues and demonstrates insulin sensitivity. This 
method requires the subject to fast for 12 hours, then inserting a catheter into a 
vein in the left upper arm in order to pump a continuous infusion of insulin and 
glucose over a two-hour period (plasma glucose was measured every five minutes 
in order  to maintain and adjust the rate of glucose being infused) and inserting 
another catheter into a vein in the same hand in order to withdraw samples of 
blood every 30 minutes during the two-hour period to measure serum free insulin 
and free fatty acid concentrations.  Before the insulin infusion, they took samples 
of blood to measure fasting glucose, glycosylated hemoglobin, triacylglycerols, 
total and LDL cholesterol, free fatty acids, fatty acid composition of serum 
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phospholipids, and serum free insulin concentrations.  They measured body 
composition by magnetic resonance imaging.  
 Weight loss occurred gradually over time in both groups at a similar rate; 
average weight loss in the orlistat group was 7.3± 0.2 kg (8.3 ± 0.1%) , which was 
similar to the placebo group’s average weight loss of 7.4 ± 0.2 kg (8.2 ±0.1%). 
Ten of the original 47 subjects did not achieve at least an 8% weight loss and 
were withdrawn from the study.  Dietary intake was similar in both groups 
throughout the study.  
 After the weight loss, in both groups, insulin sensitivity (M-value) 
increased similarly and serum fasting insulin concentrations decreased similarly.  
There were no changes in both groups to fasting plasma glucose, glycosylated 
hemoglobin, and serum fasting fatty acids. There were no significant differences 
between the two groups in mean serum free acid concentrations during the insulin 
infusion, which were slightly slower after the weight loss compared to baseline, 
There was a significant decrease in serum LDL cholesterol in the orlistat group, 
from 3.5 ± 0.2 mmol/L to 3.0 ± 0.1 mmol/L (P <  0.01)) but not in the placebo 
group; the difference in groups was significant (P <  0.05).  In the placebo group,  
serum HDL cholesterol increased slightly but significantly from 1.28 ± 0.06 
mmol/L to 1.34 ± 0.07 mmol/L (P <  0.01) but there was no change in the orlistat 
group, from 1.31 ± 0.1 mmol/L to 1.29 ± 0.1 mmol/L (P <  0.01)); the difference 
between groups was not significant. Both groups had significantly lower twenty-
four hour systolic blood pressure after weight loss and twenty-four hour diastolic 
blood pressure was also lower in both groups, but not significantly so. 
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 Treatment with orlistat provided an advantage over placebo by improving 
body fat composition through decreased dietary fat absorption. While both groups 
achieved similar losses in body weight and fat mass, and similar decreases in 
subcutaneous fat, the orlistat group lost significantly more intraabdominal, or 
visceral, fat than the placebo group.  This resulted in a lower, and more favorable, 
ratio of intraabdominal fat to subcutaneous fat, In the placebo group, the ratio of 
intraabdominal fat to subcutaneous fat did not decrease significantly.  
 There were differences in serum fatty acid concentrations between groups.  
The proportion of monounsaturated fatty acids increased significantly in the 
orlistat group but not in the placebo group. The proportion of palmitic acid (16:0), 
which is the most common saturated fatty acid in serum phospholipids, increased 
significantly in the orlistat group and not in the placebo group. The proportion of 
the essential fatty acid linoleic acid (18:2n-6), the most common polyunsaturated 
fatty acid in serum phospholipids, decreased in both groups, but to a greater 
extent in the orlistat group.  The reduction in this essential fatty acid, which has 
been reported in other studies on orlistat, may counteract the improvements to 
cardiovascular risks from orlistat treatment (e.g. the lower ratio of intraabdominal 
to subcutaneous fat). Researchers concluded that dietary fat composition, by 
affecting serum fatty acid composition, may have a stronger influence on 
metabolic processes than the total amount of dietary fat.  Weight loss, regardless 
of whether it was achieved by orlistat or placebo, resulted in improvements for all 
subjects.  Orlistat, through reducing the total amount of dietary fat that was 
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absorbed, or through changing the composition of dietary fat that was absorbed, 
may have influenced the intraabdominal and subcutaneous fat stores.   
 Exclusion criteria might have caused these studies to have limited external 
validity concerning the greater obese population (Lucas, 2001).  These studies 
demonstrated orlistat’s efficacy for inducing weight loss and causing 
improvements in many obesity-related risk factors in otherwise healthy 
overweight and obese adult subjects.  But in real life, overweight and obese 
individuals commonly have multiple comorbidities such as hepatic, 
gastrointestinal, renal, cardiovascular, psychological, and endocrine disorders as 
well as type 2 diabetes.  The complicating effects of these comorbidities are 
difficult to control in research settings.   
 On February 7, 2007, a lower dose of orlistat was approved for over-the-
counter sale by the FDA (FDA, 2007).  At 60 mg, this half-strength version of 
orlistat was branded as Alli® by GlaxoSmithKline, which had paid Hoffman-La 
Roche Laboratories $100 million for the over-the-counter marketing rights to the 
drug.  Many of the research studies on orlistat prior to its FDA approval had 
tested a 60 mg dosage as well, so additional research studies on Alli were not 
required (Schwartz, 2008).  
 With the introduction of Alli, consumers had an FDA-approved alternative 
to over-the-counter herbal weight-loss drugs that did not have the FDA’s approval 
(Bray, 2008).  Until 1998, the main ingredient in over-the-counter weight-loss 
drugs was phenylpropanolamine (PPA), which caused vasoconstriction and was 
used in cold and sinus-relief medications (FDA, 2000).  Because a few small 
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studies showed PPA caused short-term weight loss, the drug was combined with 
other ingredients and marketed as over-the-counter weight loss products under 
various names (Bray, 2008).  PPA was, however, recalled from the market in 
1998 due to the FDA’s concern that the vasoconstrictive effect would lead to 
hypertension and an increased risk of stroke (FDA, 2000).  From 1998, when 
PPA-based products were withdrawn, until 2007, when Alli was introduced, 
consumers’ only option for over-the-counter weight-loss drugs was a variety of 
herbal products whose safety was unknown.  
 Alli works identically to Xenical.  Though the dosage is half the 
prescription amount, Alli reduces dietary fat absorption by approximately 25%, as 
opposed to by 30% by Xenical.  Like Xenical, Alli has the same “treatment 
effects” as Xenical and the same theoretical potential to decrease the absorption of 
fat-soluble vitamins with long-term use.  Also like Xenical, Alli is taken three 
times daily and should be used when individuals consume a low-fat diet and 
exercise regularly.  Though a doctor’s visit is not required to begin using Alli, 
users have access to a social-support network through a free Web site, 
Alliconnect.com, sponsored by GlaxoSmithKline and moderated by paid experts.  
Additionally, a 152-page booklet providing behavioral and dietary instructions 
comes packaged with the product. 
 U.S. sales of Alli were $155 million in the first six weeks after it was 
launched in June 2007. But sales of Alli fell after those initial weeks and steadily 
declined.  Sales never regained the initial momentum.  According to 
GlaxoSmithKline’s 2007 annual report, sales of Alli for the entire first year were 
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$247.2 million (Miley, 2009). The following year, sales had fallen by 53% to 
$131 million (Miley, 2009).  Consumers might have been repulsed by Alli’s 
“treatment effects” as well as the cost: A one-month supply of Alli in 2007 ranged 
from $60 to $70 (Thomaselli, 2007).  An “industry executive” listed the 
challenges of marketing Alli in Advertising Age: “diet-pill stigmas, a challenging 
economic climate and lazy human nature-as well as a horrendous side effect” 
(Miley, 2009). Consumers expecting rapid weight loss may have been 
disappointed because Alli is intended to cause gradual and moderate weight loss 
(Miley, 2009).  One wonders if the low-fat diet, exercise, and other lifestyle 
modifications that the manufacturer recommended in conjunction with Alli were 
sufficient to cause weight loss, making Alli unnecessary.  
 The FDA was first made aware of a possible link between orlistat use and 
severe liver injury in 1999.  Potential orlistat-associated cases of severe liver 
injury, including the need for organ transplant and culminating as the cause of 
death, have been reported since, with an uptick when Alli entered the 
marketplace.  Orlistat – sold as Xenical or Alli – remains available to U.S. 
consumers, however, because the FDA has not confirmed orlistat causes severe 
liver injury and because the causal relationship, if valid, occurs rarely (FDA, 
2010).  The FDA conducted a post-market adverse effect study of Xenical and 
Alli and determined that of approximately 40 million people around the world 
who have taken orlistat, 12 cases, all outside the U.S., had possible Xenical-
associated severe liver injuries.  Within the U.S., only one case – an individual 
who had used Alli – linked orlistat with severe liver injury.  Xenical was not 
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associated with any cases of severe liver injury in the United States.  The FDA 
warned consumers to be vigilant of symptoms that indicate liver damage and 
ordered package labeling to be changed to include the reports of rare, yet severe 
liver injury.  
 Purchasing Alli over the counter could mean visiting a traditional retail 
store, but it could also mean ordering the drug online via an Internet retailer (Fox, 
2005).  One danger of purchasing Alli, or any other medication, from an Internet 
source is that the product could be fake.  In 2010, the FDA warned that a 
counterfeit form of Alli was being sold online, including eBay.com (FDA, 2010).  
The product, instead of 60 mg orlistat, contained varying amounts of sibutramine, 
which is no longer sold in the United States.  Sibutramine is contraindicated for 
individuals with cardiovascular disease because it can increase the risks of strokes 
and heart attacks.  In some cases, samples of counterfeit Alli contained megadoses 
of sibutramine.  No counterfeit Alli was discovered being sold in retail stores.  
 The main difference between Xenical and Alli is Alli’s over-the-counter 
accessibility, at least in theory.  Actually, Xenical is available for sale on the 
Internet as well.  Though it is not supposed to be sold without a prescription from 
a physician, Xenical is available from Web sites such as Xenical Direct (Xenical 
Direct, 2011), which offer a “free, online consultation” before purchasing the 
product.  The consultation consists merely of a handful of questions about the 
consumer’s height, weight, and medical history prior to the screen that prompts 
the consumer to order the product.  The Web site asks for a physician’s name and 
address, but does not require a prescription to complete the transaction.  There is 
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nothing to prevent Xenical, like many other medications designed for a specific 
use by a specific population, from being ordered by individuals who should not be 
taking it, such as children, pregnant women, or individuals with liver or 
gallbladder disease. 
 Alli’s days of being available on the market are ending, however.  In April 
2011, GlaxoSmithKline announced it would sell off the Alli product line, among 
other drug products, less than four years after it was launched in June 2007 (GSK, 
2011).  
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Section 2  
Framing Theory 
 Research studies based on framing theory have proliferated in the fields of 
sociology, economics, linguistics, social-movements research, policy research, 
communication science, political communication, public-relations research, and 
health communication (Van Gorp, 2007).  There is, however, no universal 
theoretical model of framing, even within a single field.  Among mass 
communication researchers, there is controversy regarding the meaning of frames 
and framing, the cognitive processes involved in framing and how framing relates 
to other media-effects models such as agenda-setting and priming.  
 Framing theory can be applied to various types of news media coverage of 
a broad range of issues. This study applies framing theory to newspaper coverage 
of the weight-loss drug orlistat in its prescription form as Xenical (120 mg 
orlistat) and its over-the-counter version, Alli (60 mg orlistat). There are no other 
studies that investigate the framing of weight-loss drugs in the research literature.  
 The frame used to describe an issue, as noted by Entman (2004), is a 
powerful communication tool because the frame determines whether people pay 
attention to the issue, how they understand it, how and whether they remember it, 
and how they assess the issue and decide to take action.  The way that a weight-
loss drug is framed in the media influences public opinion about its usage and 
affects people’s decisions to request a prescription for the drug (e.g., Xenical) or 
to buy the drug over the counter (e.g., Alli).     
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 Generally speaking, frames help to organize information. Tversky and 
Kahneman’s (1981) research in prospect theory revealed the power of frames to 
affect people’s perceptions of the options in decision-making situations..  From a 
cognitive point of view, frames are the mental structures in an individual’s mind 
that organize and manage information arriving from the outside (Scheufele, 
2000). On the other hand, the constructionist perspective defines frames as 
ubiquitous social constructions that are inseparable from culture as a whole (Van 
Gorp, 2007).  
 This study applies a classic journalism-oriented approach to the concept of 
framing, viewing it as a process that happens during media production and 
performed by the individual creating the communicating text, i.e. the reporter 
writing a newspaper article.  Framing involves selecting certain pieces of 
information about a topic to emphasize, while simultaneously excluding certain 
others for the purpose of increasing the salience of the selected portions to the 
consumer (Entman, 1993). The more salient information is, the more likely it is 
that consumers will notice and remember it. Building a frame requires selecting 
traits to describe the topic; by definition, while some traits are included, others 
must be excluded. Emphasizing selected traits enhances their salience in two 
ways: the audience perceives the selected traits to be more important than others 
when making a judgment about the issue, and is able to recall those selected traits 
quickly when thinking about the issue (Weaver, 2007).  
 Because the nature of reality is somewhat subjective, there are multiple 
ways to view and describe a situation or a topic. A frame promotes a specific 
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viewpoint on the issue by emphasizing certain traits over others. Aubrey (2010) 
demonstrated in a two-part study that frames have a powerful influence on how 
individuals perceive advice on health behavior change.  The two components of 
the research were a content analysis of 426 cover headlines of the five highest-
circulating U.S. women’s health magazines (Shape, Fitness, Self, Health, and 
Women’s Health) that investigated frames of health advice and an experiment on 
103 college-aged women that demonstrated the connection between their 
exposure to articles from women’s health magazines that used either appearance-
focused frames or health-focused frames and their resulting responses about self-
objectification, body shame and motivations to exercise, as measured by 
questionnaires specifically designed to assess these variables.  
 For the content analysis, researchers consulted the Audit Bureau of 
Circulation’s list of the top-100 magazines, by circulation, and chose the top five 
magazines targeted at women and about health: Shape (circulation: 1.7 million), 
Fitness (1.6 million), Self (1.5 million), Health (1.4 million), and Women’s 
Health (1.2 million).  The strategy for finding articles from each publication was 
to select two issues randomly from each of six consecutive years from 2003 to 
2008.  The unit of analysis was the cover headline of a story that appeared on a 
magazine cover.  Each of the 55 magazine covers had between five and 12 (mean 
= 7.82, SD = 1.59) cover headlines. The coding scheme identified several possible 
frame categories, including appearance frame (defined as instructing readers to 
change a behavior in order to look better), body competence frame (defined as 
instructing readers to change a behavior in order to improve a physical function, 
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such as fitness, strength or flexibility), and health frame (defined as instructing 
readers to change a behavior in order to enhance an intrinsic, but not cosmetic, 
aspect of health). A weight-loss frame category was added because there were 
many cover headlines about weight-loss that could be classified in both the 
appearance frame and health frame categories.  
 Three coders trained for 15 hours, refining the coding scheme in multiple 
iterations of a pilot study, before coding the final sample of articles 
independently. Reliabilities, measured using Cohen’s kappa, were calculated 
based on the coding of four magazine issues that were not part of the final sample.     
 Out of the 426 cover headlines, 33.3% (n = 142) were coded as 
appearance frames and 29.3% (n = 125) were coded as health frames, 19.0% (n = 
81) were coded as weight loss frames, and 3.3% (n = 14) were coded as body 
competence frames. The remaining 15% (n = 64) cover headlines were classified 
as other/miscellaneous.  Researchers found that appearance frames were used just 
as often as health frames and much more often than body competence frames.  
Therefore, the appearance-related traits about health advice were the most often 
selected, and became most salient in the audience’s mind, relative to intrinsic 
health-related traits and body competence-related traits.  
 Because most of the articles about weight loss emphasized losing 
moderate amounts of weight, the researchers concluded that the focus of these 
articles was cosmetic rather than medical and speculated that if these articles had 
been coded in the appearance frame category instead of in a separate weight loss 
frame category, then the majority of all the frames (52.3%, n = 223) would be 
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classified as appearance frames.  Appearance frames would dramatically 
outweigh health frames in this case.  
 In the second part of the study, an experiment was conducted among a 
sample of 103 women, aged 18 to 30, at a public Midwestern university.  They 
were assigned to review six magazine articles, each 100-200 words in length, 
from women’s health magazines (e.g. Self, Shape, Fitness). Subjects were 
assigned to view articles that were coded as utilizing either appearance frames (n 
= 53) or health frames (n = 50). Then the subjects completed questionnaires 
designed to assess self-objectification, body shame, and motivations to exercise. 
Among readers who were assigned to review the articles containing appearance 
frames, their responses exhibited increased body shame and increased 
appearance-related motivation to exercise in comparison to the readers who were 
assigned the health frames.  Researchers suggested that in the long term, 
appearance frames of health advice promote an extrinsically-motivated approach 
to health that is focused on enhancing looks, but emphasizing looks rather than 
health can be counterproductive because it can lead to body shame when 
individuals feel their looks fall short of their high expectations. Health frames 
which focus on intrinsic motivations (e.g. feeling more energetic) rather than on 
cosmetic improvements may be more likely to lead to long-term success at 
adopting health behavior change.  
Frames are powerful communication devices. A frame can define a 
problem in a particular way, imply the causes of a problem, make a moral 
judgment, and promote solutions to the problem at hand (Entman, 1993). Saguy 
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and Almeling (2008) studied the joint influence of medical science media and the 
mainstream news media on the creation of frames that define obesity as a social 
problem. They created a codebook to analyze how obesity was presented in a 
sample of texts that included 20 scientific articles from two special issues about 
obesity by the Journal of the American Medical Association (JAMA) in 1999 and 
2003, eight press releases related to the studies covered in those JAMA issues, 
and 128 articles from newspapers that also discussed the studies in the JAMA 
issues (60 articles were relevant to the 1999 JAMA issue and 59 were relevant to 
the 2003 JAMA issue). To locate the news articles, they utilized the LexisNexis 
database and entered the search terms “obesity” OR “weight” in the full text AND 
“American Medical Association” in the full text for three months after each of the 
JAMA issues was published. All of the articles were classified in LexisNexis as 
either General News (n = 66), World News (n = 8), News Wires (n = 24), 
Business News (n = 21), University News (n = 4), or Medical News (n = 5). All 
articles were at least 500 words to allow sufficient space for the themes to develop 
in the texts for coding.  Articles from peer-reviewed journals were excluded to 
insure that the sample was taken from news sources rather than scientific 
publications. To locate the press releases on any of the JAMA articles from those 
two issues on the World Wide Web, they used the Google logarithmic search 
engine. They created combinations of the article title and author, the year of 
publication, and the word “embargoed” in the searches.  Among the eight press 
releases in the sample was an official JAMA press release for each issue, two 
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press releases from the National Institutes of Health (NIH) on the research studies 
they funded, and press releases from the lead author’s academic institution.  
The codebook contained over 200 variables for the scientific articles, the 
article abstracts, the press releases, and the news media sample. Their tests of 
intercoder reliability had a mean of 90%. They measured dramatization of the 
obesity problem by coding for whether or not the article presented obesity as a 
public crisis, an epidemic, used war metaphors such as “battle of the bulge” or 
“time bomb”, or blurring the lines between the categories of obesity and 
overweight (e.g. describing an individual with a BMI > 40 as representative of the 
overweight U.S. population, rather than the obese population).  One way to 
mitigate alarmist reporting about obesity is to acknowledge the scientific debates 
over the risk of obesity, such as the extent of the health risks that are associated 
with obesity, the appropriateness of current weight guidelines, and whether 
physical fitness is attainable despite overweight or obesity. Therefore, the 
codebook included measures of whether these scientific controversies were 
discussed. To measure how the medical and news reports assigned blame for 
obesity, they coded articles for the assertions that obesity is caused by bad 
individual choices, including those related to diet and exercise, social or structural 
factors (e.g. restaurant portions, food advertising), and genetic factors. They 
coded for proposed solutions to the overweight and obesity problem, such as 
individual changes to exercise or diet, policy changes, weight-loss drugs, and 
weight-loss surgery.  
 83 
Results of the study suggest that the news media, consistent with the 
scientific reports from which they draw, portray obesity as a crisis. The news 
media, however, exaggerate the perception and the scope of the obesity problem 
by using frames that dramatize overweight and obesity describing it as not just a 
crisis, but as an epidemic and a war, and confusing the categories of obesity and 
overweight. The news media are more likely than the science media to assign 
individual blame for overweight and obesity.  The news media reinforce a one-
sided view of the obesity issue by not reporting on the scientific controversies in 
the research literature about obesity (perhaps body weights that exceed the norm 
are not indications of pathology, but rather natural diversity in human body size 
and perhaps obesity poses less health risks than some believe). The authors 
recommend that news reporters temper their alarmist tone by quoting from 
skeptical experts who can advocate for opposing viewpoints.  
In addition to these findings, they discovered that weight-loss drugs were 
mentioned as a solution to the obesity problem in 20% of the 1999 science sample 
and in 30% of the 1999 news sample, and in 2003, weight-loss drugs were 
discussed in 60% of the science sample and 25% of the news sample. In the news 
media, weight-loss drugs were repeatedly stated to be ineffective and inferior 
weight-management tools in relation to behavior modification.   
 External factors such as social norms and values, organizational 
constraints, journalistic routines, and ideological or political orientations of 
journalists influence the usage of frames (Scheufele, 1999). As public discourse 
about an issue evolves, issues are reframed, reflecting changes in cultural 
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attitudes. Lawrence (2004) studied the changes in frames of obesity over time by 
reviewing samples of news texts between 1985 and 2003 consisting of 136 page-
one stories from all sections and editorials about obesity published in the New 
York Times and 89 abstracts of U.S. prime-time evening broadcast television news 
segments about obesity.  Changes in obesity frames reflected the shift in public 
opinion from attributing obesity to individual causes to linking obesity to 
environmental causes. 
 Lawrence identified a continuum of discourse, with individualizing frames 
on one end and systemic frames at the opposite end.  Individualizing frames 
emphasize personal responsibility and define the afflicted individual as the sole 
cause of the problem and the source of the solution.  Systemic frames take a 
broader view of the issue and use government, business, and social-structural 
factors, rather than the individual affected by the issue, to define the cause and 
solution of the problem.  Frames about obesity and many other public health 
issues, in reality, are neither only individualizing nor systemic, but contain 
elements of both approaches.  As the public debate about obesity moved from the 
individualizing end of the continuum to the systemic end between 1985 and 2003, 
the public policy environment became more receptive to policy changes that 
directed the government to take ownership of the obesity issue and highlighted the 
need for change from stakeholder institutions. There were different types of 
frames used to portray obesity throughout this time period.   
 To identify the multiple, competing frames about obesity, research was 
conducted by reading articles from news sources and scholarly publications, 
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books, Web sites, and via personal interviews with health experts. Frame 
categories included biological, behavioral, and environmental frames.  The 
biological frame aligns with the individualized approach and with a medicalized 
view of obesity that defines its causes as purely physiological and contained 
within the obese body itself (e.g. genetic disposition). Behavioral causes of 
obesity (e.g. lack of exercise) focus on individual choices, but can also been seen 
as responses chosen from a limited range of options, dictated by the environment.  
The environmental frame places the causes of and solutions for obesity (e.g. 
marketing of junk food in schools) in the realm of external influences and public 
policy choices.  
 The sample of texts included 136 page-one articles from all sections and 
editorials from the New York Times between 1985 and 2003 and 89 abstracts of 
the evening network news stories about obesity between 1985 and 2003, drawn 
from the Vanderbilt Television News Archives. The year 1985 was chosen as a 
starting point because during that year, the National Institutes of Health declared, 
for the first time, that obesity posed a major threat to public health. Each news 
article text was coded for its topical focus and the claims made about the causes 
of and solutions for obesity.  For the television news abstracts, the topical focus of 
each story was coded, but the abstracts did not provide enough textual detail to 
allow for coding for specific claims about obesity. To establish generalizability of 
the data from the news sample in this study, articles about obesity were selected 
from ten other major newspapers using the Nexis database and coded as well. 
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 A coding scheme was developed for the content analysis. Two individuals 
performed the coding independently. There were 72 possible points of agreement.  
The coders reached 87% agreement initially, which increased after points of 
disagreement were discussed and found to be results of errors in missing phrases 
and not true differences in coding.   
 Results of the coding of the news articles and television news abstracts 
showed similar patterns in the changes of the frames that were used over time.  
The prevalence of the environmental frame and the behavioral frame increased 
dramatically in relation to the biological frame between 1985 and 2003. These 
patterns were consistent with the frames used in the sample of newspaper articles 
drawn for generalizability.  
  Kim and Willis (2007) reached similar conclusions in their content 
analysis of how the news media frame responsibility for obesity, which showed a 
similar shift away from frames that emphasized individualized causes and 
solutions toward frames that focused on societal causes of and solutions for the 
obesity epidemic.  Their research focused on a sample of 300 articles published in 
six major U.S. newspapers (the New York Times, the Washington Post, Chicago 
Sun-Times, the San Francisco Chronicle, and the Houston Chronicle) and 200 
transcripts from news stories aired by three major television networks (ABC, 
NBC, and CBS) between January 1995 and August 2004.  To locate both the 
articles and transcripts in the LexisNexis database, they used the keywords 
“obesity” or “obese” in the fields for headline, lead paragraphs, or index terms. 
The search yielded 4,552 articles and 1,476 transcripts. Duplicates and irrelevant 
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articles (e.g. pet obesity) were excluded. The researchers took a systematic 
sampling to reach the final sample of 300 articles and 200 transcripts.   
 The codebook designated four main frame categories: personal causes 
(e.g. consuming too much food), societal causes (e.g. lack of physical activity 
programs in schools), personal solutions (e.g. medications such as weight-loss 
drugs), and societal solutions (e.g. taxing unhealthy food). After undergoing 
training and conducting pilot studies, two coders coded the articles and 
transcripts.  Intercoder reliability, corrected for agreement by chance (Scott’s pi), 
was calculated by coding a random subsample of the data (n = 75, or 15%). The 
range of intercoder reliability was 0.74 to 0.86 with a mean of 0.81. 
 Findings demonstrated a dramatic rise in overall news coverage of obesity. 
In 1995, there were 277 articles published in the six newspapers, but in 2003 there 
were 950 articles published. There was an increase in network news coverage 
from 163 news items in 1997 to over 280 items in 2003.  As hypothesized, 
personal causes of obesity were mentioned far more often than societal causes by 
a ratio of 2.4 to 1 (291 mentions of personal causes vs. 119 mentions of societal 
causes).  Personal solutions to obesity were mentioned much more often than 
societal solutions to obesity, for a ratio of 4.3 to 1 (512 mentions of personal 
solutions to 118 mentions of societal solutions.  Mentions of societal causes of 
obesity increased from less than one in ten references in 1995 to over five in ten 
in 2004. The rise in usage of news frames that emphasize societal responsibility 
for obesity reflects the evolving definition of obesity as a public health issue 
rather than an individual health issue.   
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 In addition, mentions of medical treatments (e.g. weight-loss drugs and 
gastric bypass surgery), a subcategory of the personal solutions category, 
decreased significantly after 1997, the same year that the FDA removed the 
weight-loss drug fen-phen from the market. The authors attribute this decrease in 
coverage to the publicized side effects of weight-drugs and complications of 
gastric bypass surgery. 
Framing is a powerful way of shaping public opinion. Knowing how 
framing in the popular media works can help health care practitioners understand 
how their patients interpret the health information they receive from newspapers, 
magazines, television, and the Internet. Public health advocates, working with 
journalists, can encourage the usage of frames that emphasize the benefits of 
supporting policies designed to improve the long-term health of society despite 
short-term costs to individuals and stakeholders who are resistant to change.   
Related Theories: Agenda-setting and Priming 
 Communication scholars frequently apply framing theory, agenda-setting 
theory, and priming theory to analyze how mass media influence the opinions and 
behaviors of audiences (Scheufele and Tewksbury, 2007).  While the news media 
guide the audience’s thinking about issues being covered (framing) and direct the 
audience’s attention toward certain issues by choosing what to report on (agenda-
setting), priming occurs when an individual audience member views a television 
news broadcast or reads a news article and certain features of the story activate 
the formation of perceptions about how to judge the issues being presented 
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(McCombs,1997).  Framing, agenda-setting, and priming are distinct, yet related 
concepts.   
 Agenda-setting theory asserts that the set of issues that the news media 
covers determines what the public perceives as important (McCombs, 1997).  
Agenda-setting does not, however, state that the news media push a particular 
viewpoint for or against the issue, only that the issue is important enough to be on 
the media agenda and therefore should be on the public agenda.  Setting the news 
media agenda is a routine that occurs during news production as certain topics are 
chosen to report on and topics are prioritized relative to each other (McCombs 
and Shaw, 1972).   
 McCombs and Shaw introduced agenda-setting theory in 1972 with the 
publication of their research on the effects of newspaper coverage on setting the 
public agenda. Their study focused on Chapel Hill, North Carolina, voters’ 
attitudes regarding the 1968 United States presidential election. They interviewed 
100 citizens between September 18 and October 6, 1968, about their perceptions 
of the central issues of the campaign and compared those to the actual content in 
the news media. Researchers developed a coding scheme containing 15 categories 
of campaign issues and other campaign news to analyze the content of news 
collected from major media sources: the Durham Morning Herald, Durham Sun, 
Raleigh News and Observer, Raleigh Times, New York Times, Newsweek, and 
NBC and CBS evening news broadcasts (McCombs and Shaw, 1972).  Results 
revealed a strong correlation between the issues covered in the news and what the 
public thought were the key issues of the campaign (McCombs and Shaw,1972). 
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 Agenda-setting is one of the many functions illustrated by the gatekeeping 
concept, a popular metaphor for describing how a series of decisions to include 
and exclude information lead to the production of media (McQuail, 2005). 
Gatekeeping in mass communication can include decisions about selecting which 
news items to transmit, how to manipulate news messages, when to disseminate 
news, and overall, how to construct social reality using news information 
(Shoemaker, 2001).  Four types of news gates, or gatekeeping-factors, influence 
the development of news content: the reporter’s judgment about what is 
newsworthy, journalistic norms and practices that dictate how sources and 
reporters work together, economic restrictions in news production, and 
technological limitations  (Livingston and Bennett, 2003).   
 The news media can influence public opinion in favor of interest groups, 
policymakers, and journalists themselves because the quantitative amount of 
attention given to a topic by these stakeholders is a factor in creating the media 
agenda (Scheufele and Tewksbury, 2007).  Subsequent studies have examined the 
relationship between the media agenda and the public agenda, expanding the 
concept of the agenda to include personal issues (e.g. health) as well as political 
issues (McCombs, 1993).   
 Agenda-setting can play a powerful role influencing public opinion and, 
therefore, action, regarding health-related issues.  According to Yang and Stone’s 
2003 research, people receive 80% of their information about news and public 
affairs from mass media, compared to 20% from interpersonal communication 
(Jones, Denham, and Springston 2006). Jones, Denham, and Springston (2006) 
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compared the effects of mass media (magazines, newspapers, and television) and 
interpersonal communication on breast cancer screening practices among college-
aged women and their middle-aged mothers (n = 284). They hypothesized that 
mass media would be more influential on screening adoption rates among the 
older women than the younger women because they would be more likely to have 
been personally affected by breast cancer in some way and to seek information 
about it from media sources. They also hypothesized that for the younger women, 
interpersonal communication (specifically from their mothers) would be more 
influential than mass media on breast cancer screening practices, because they 
were less likely to be affected by breast cancer personally and less likely to seek 
out information about it from media sources.  Researchers distributed 
questionnaires to college-aged women and their mothers about their exposure to 
media sources of information about breast cancer (e.g. television, magazines, 
newspapers), breast cancer screening practices (e.g. breast self-exams, 
mammograms), interpersonal sources of information about breast cancer (e.g. 
friends, relatives, physician), and family history of breast cancer.  Consistent with 
the hypotheses, findings showed that the mothers received most of their 
information from media sources, while the daughters received most of their 
information from interpersonal sources.  Among the mothers, reading a news 
magazine article about breast cancer had highly significant (P < 0.001) effects on 
the frequency of undergoing mammograms.  Discussing breast cancer with a 
relative was predictive of more frequent screening practices among the younger 
women. It is logical to conclude that the daughters relied on their mothers for 
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information about breast cancer, consistent with the two-step flow of information 
theory of communication.  By providing news coverage on breast cancer, the 
media placed breast cancer on the public agenda.  Agenda-setting increased the 
salience of breast cancer information to the audience of older women, who 
transmitted the information to their daughters.  
 Communication scholars have defined two levels of agenda-setting.  The 
first level focuses on the salience of one issue relative to others in the news 
(Weaver, 2007). By granting specific issues a great deal of news coverage or 
conspicuous placement (e.g., the front page of a newspaper above the fold), the 
news media can influence the audience to consider those issues more important 
than others (Scheufele and Tewksbury, 2007).   
 The second level of agenda-setting examines the salience of the attributes, 
or characteristics, of an issue (Weaver, 2007).  The most salient characteristics 
form a set of criteria that the audience uses to form opinions and make judgments 
about the issues (McCombs, 1993). There is conflict in the research literature 
about whether or not the second level of agenda-setting is synonymous with 
framing.  
 McCombs conceives of framing as an extension or refinement of agenda-
setting (Scheufele and Tewksbury, 2007).  He defines framing as emphasizing 
certain characteristics of an issue, which increases their salience (Scheufele, 
2000), which sounds equivalent to his explanation of the second level of agenda-
setting as using a set of the most salient characteristics of the issue to judge the 
issue: (McCombs, 1997).  
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 Different conceptual definitions of framing complicate the debate.  A 
constructionist view of framing defines framing as a cultural phenomenon that is 
far larger than agenda-setting. McCombs, Shaw, and Weaver  (1998) and Tversky 
and Kahnemen (1973) tend to accept framing as similar to agenda-setting because 
they view both processes as being based on the concept of accessibility, or 
retrievability, of information from the memory.  
 On the other hand, some researchers who also take a cognitive view of 
framing argue that framing and agenda setting are based on different theoretical 
premises and are therefore inherently different.  Scheufele points out that framing, 
by manipulating linguistics to describe an issue, causes an individual to utilize an 
existing paradigm or schema to interpret the information about the issue 
(Scheufele, 2000).  This is a very different cognitive processing model than 
accessibility.  In addition, framing goes beyond selecting which attributes to 
emphasize (the definition of the second level of agenda setting) and attempts to 
control the audience’s perceptions about multiple dimensions of the issue by 
using semantic techniques that imply causes and solutions, make assessments, and 
define issues subjectively (Weaver, 2007).   
 Yet another alternative conceptual distinction between the second level of 
agenda-setting and framing is that the salience of frames is based on the relevance 
of the traits used to describe the issue  (Entman, 1999). Entman points out that 
research by Nelson and colleagues in 1996 and 1997 reinforces the view that 
some frames resonate more because certain emphasized characteristics are 
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perceived to have greater importance to the issue, and not because they are more 
accessible in the audience’s memory. 
 Priming theory frequently intersects and overlaps with framing theory and 
agenda-setting theory. While agenda-setting is a media routine that turns the 
audience’s attention toward certain issues and framing is a journalistic approach 
that shapes how the audience perceives issues presented in the news, priming is a 
cognitive process that occurs in the mind of the individual when exposure to news 
content activates a set of criteria for evaluating the issues or subjects being 
covered (Scheufele and Tewksbury, 2007). The concept of priming originated as a 
speculation by Weaver, McCombs, and Spellman in their 1975 study of the 
effects of Watergate news coverage. The trio proposed that through priming, the 
media influence audiences to use specific standards to judge political figures, with 
these standards leading toward or away from a particular political conclusion  
(Weaver, 2000).  
 The term priming was first used in Iyengar and Kinder’s 1987 research 
experiments, which revealed a connection between the agenda-setting effects of 
television news reports and audience opinions of the U.S. president. They 
concluded that this connection was the effect of priming, defined as increasing the 
salience of particular issues or attributes and therefore more easily accessed in the 
memory and used to form beliefs (Weaver, 2000). Priming can influence the 
audience’s opinion in positive and negative directions. An analysis of agenda-
setting and priming effects used a sample of front-page articles about the 
economy from two leading Israeli newspapers during five election years and data 
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from public-opinion surveys from the same time period. The study revealed that 
priming can take a positive, negative, or neutral tone toward an object or 
attributes and sway public opinion in that direction as well  (Sheafer, 2007).   
 In the communication-research literature, there is widespread agreement 
that priming is an extension of agenda-setting.  Studies on priming position 
agenda-setting as the independent variable and priming effects as the dependent 
variable (Scheufele, 2000).  Studying priming is equivalent to studying the effects 
of agenda-setting on public opinion (Weaver, 2007).  Both agenda-setting and 
priming are founded on the principle of accessibility; people use the most readily 
accessible, or retrievable, information from their memory to make decisions 
(Scheufele and Tewksbury, 2007).  
 While priming has much in common with agenda-setting, priming differs 
from framing. Framing has a broader range of functions than priming. In contrast 
to agenda-setting and priming which are based on accessibility, framing relies on 
a model of information-processing that is based on influencing how information is 
received and categorized (Weaver, 2007).  Framing is based on the principle of 
applicability; framing creates a connection between two concepts, e.g. by 
persuading the audience to believe that Attribute A is applicable to Issue B 
(Scheufele and Tewksbury, 2007).  A key distinction is that the passage of time 
affects accessibility (and therefore the effects of agenda-setting and priming) far 
more than applicability (and therefore the effects of framing) (Scheufele and 
Tewksbury, 2007).  
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 Framing, agenda-setting, and priming are interrelated models of how the 
news media affect the formation of opinions and influence behaviors.  By 
understanding how these mechanisms work, practitioners in health-related fields 
can partner with the media more effectively to increase the effectiveness of health 
campaigns aimed at the public. 
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Section 3 
Mass Communication Theories 
 Newspapers, the focus of this research study, continue to be highly trusted 
sources of health information. A 2002 Gallup Poll on the use of media reports of 
health and medical news found that 64% of respondents reported having a great 
deal or a moderate amount of trust in information received from newspapers 
(Minnesota Medical Association, 2003). There is no doubt that television, radio, 
newspapers, magazines, and the Internet influence the attitudes and behaviors of 
billions of individuals to some extent. But this amount of influence varies greatly 
in different circumstances. Research on how mass communication works has 
generated many theoretical models, shaped by history, politics, social science, and 
technology (McQuail, 2005). 
 This section will contribute to an understanding of how messages from the 
mass media, in the form of newspaper articles, contribute to people’s decisions 
about health behaviors such as using weight-loss drugs. Major mass 
communication theories include the magic bullet (or the hypodermic needle) 
theory, cultivation theory, McGuire’s communication/persuasion model, and the 
diffusion of innovation theory.  
Magic Bullet Theory 
 From the turn of the century until the 1930s, people believed that the mass 
media, in the form of newspapers, film, and radio, had an extremely powerful 
influence on public opinion. Political propagandists used film to create support for 
World War I. Messages from advertisers influenced consumer behavior. Public 
 98 
concern about the effect of movies on the actions of individuals, especially on 
young people, led to a series of psychological experiments from 1933 to 1935 
known as the Payne Fund Studies. The results, which some believed were based 
on flawed research methodology, seemed to support the idea that the audience 
was incapable of resisting the powerful messages being transmitted through 
movies (Martinson, 2004).   
 Results of the Payne Fund Studies reinforced magic bullet theory (or 
hypodermic needle theory), an approach which dominated early communications 
research, in which the audience plays a passive role and the media has 
“immediate, uniform, and powerful effects” on anyone exposed to its messages 
(DeFleur, 1998). The metaphor of the media as “a dangerous drug or a killing 
force that directly and immediately penetrate a person’s system” was widely 
accepted (Martinson, 2004). Brown’s 1937 article  “Media of Propaganda” 
demonstrated society’s deep concern about the power of the press, the radio, and 
the motion picture to incite support for war among an audience unable to resist 
mass media’s messages (Brown, 1937).   
 Progressive propaganda critics presented an alternative paradigm to 
traditional magic bullet theory. They focused on the role of institutions in creating 
the media messages designed to sway public opinion and they viewed the 
audience as having the potential to resist media messages through critical thinking  
(Sproule, 1989). The work of progressive propaganda scholars was considered a 
“socially divisive anachronism” during the post-World War II era and fell out of 
favor in the field (Sproule, 1989).  
 99 
 In 1938, a CBS radio broadcast presented a fictional production of “War 
of the Worlds.”  Designed to entertain the public, the broadcast had the 
unintended effect of discrediting magic bullet theory by eliciting a non-uniform 
response from the audience (Martinson, 2004). There was no single mass 
response to the broadcast describing a Martian invasion of the planet; some 
people thought it was a real news story and reacted with panic and fear, but others 
did not (Martinson, 2004). This was a direct contradiction of one of the chief 
tenets of magic bullet theory, the expected uniformity in the audience’s reception 
of and response to the media’s message (Sproule, 1989). Data from the radio 
station revealed that the level of education was the best way of predicting whether 
the listener would accept the information as real (Martinson, 2004).  
 In the wake of the “War of the Worlds” program, the media’s influence 
began to be perceived as limited and dependent on audience-related factors 
(DeFleur, 1998). The “direct effects” model of the media evolved into “limited 
effects, minimal effects, conditional effects, and the ‘two-step flow’” (Servaes, 
1995). A study in Erie County, OH, of the 1940 United States presidential 
elections generated the concept of the “two-step flow of communication” 
(Servaes, 1995). Instead of a direct relationship between the “stimulus” and 
“respondent”, as in the magic bullet theory, there is a “two-step flow” of influence 
(McQuail, 2005). According to the two-step model of communication, the 
media’s messages flow to opinion leaders who then disseminate the information 
to people on whom they are influential (Katz, 1957). The population is divided 
into two groups: “active” and “passive” participants, or “opinion leaders” and 
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followers” (Servaes, 1995). In the late 1940s, Lazarsfeld and his colleagues in 
Columbia University’s Bureau of Applied Social Research asserted that media 
effects are dependent on an individual’s pattern of media consumption and social 
network, which tend to create support for pre-existing opinions rather than 
changing them (Scheufele, 2007).   
Cultivation Theory 
 Cultivation theory originally focused on the long-term influence of 
television viewing on the audience’s perceptions of reality, but has been expanded 
to include the cumulative effects of consuming all forms of mass media. The 
original cultivation theorist, George Gerbner, viewed television as an 
enculturating force in society whose job is to condition viewers by presenting 
views of reality that support the established social order (Gerbner, 1976). 
Exposure to television reinforces norms of “social reality” by presenting the 
television version of reality as  “what most people do”, as well as portraying 
norms for individual behavior by showing “personal reality” with which the 
viewer identifies (Austin and Meili, 1994). 
 A cultivation analysis compares the perspectives represented on television 
with views expressed by the audience; the hypothesis is that the greater the 
amount of television watched, the more the audience’s views will correspond to 
the version of reality shown on television (McQuail, 2005). Gerbner created a 
system of cultural indicators, or cultural messages, being expressed through 
television (Potter, 1993).   
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 Gerbner’s 1976 study revealed that heavy exposure to television (greater 
than 4 hours per day), which presents a more violent version of reality, creates 
excessive fears about danger and mistrust (Gerbner, 1976).  Hammermeister and 
colleagues (2005) found an association between watching television at least two 
hours daily and exhibiting negative psychosocial health characteristics such as 
loneliness and depression (Hammermeister, Brock, Winterstein, and Page, 2005).  
Many studies have established that heavy television viewing is associated with 
negative health conditions such as obesity, poor nutrition, body image issues, and 
aggressive behaviors; television programs display adverse health behaviors such 
as smoking cigarettes, alcohol abuse, and illicit drug use and television content 
commonly includes messages condoning violence, exaggerated sexuality, and 
distorted body-image (Hammermeister, 2005). Hampl and colleagues (2006) used 
cultivation theory to explore the cumulative effects of direct-to-consumer (DTC) 
advertising for prescription medications on consumer behavior; they suggested 
that continual DTC advertising fosters among consumers a sense that an illness is 
more prevalent in society than it actually is and that the prescription medication 
being advertised would wholly resolve a particular health issue (Hampl, Bramlett-
Solomon, and Wharton, 2006).   
 In their cultivation analysis that focused on the influence of children’s 
television programming on children’s food preferences and views about nutrition, 
Signorielli and Staples (1997) reported a strong positive correlation between 
watching more television and preferring an unhealthy foods over healthy one, and 
a strong positive correlation between watching more television and perceiving 
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unhealthy foods to be healthy. They concluded that the pervasive television 
messages promoting unhealthy foods to children are a factor in creating 
misconceptions about nutrition and weight issues among children.   
 Cultivation theory has its limitations, however. As in the magic bullet 
theory and the two-step flow of communication, in cultivation theory, the 
underlying assumption is the audience is passive, not active, and accepts 
messages from mass media uncritically (Hesse-Biber, Leavy, Quinn, and Zoino, 
2006).  Austin and Meili (1994) demonstrated that parental role modeling 
modified television’s influence on children’s intentions about drinking alcohol. 
Hesse-Biber and colleagues note that despite that the barrage of messages from 
the media idealizing an extremely thin female body shape and promoting this 
ideal as a realistic and attainable goal, there are some women who are able to 
resist these destructive messages; more research is needed to determine the 
psychological and social factors that protect against developing eating disorders 
(Hesse-Biber et al., 2006). Potter (1993) argues that the concepts on which 
cultivation theory is based should be redefined in order to strengthen its value as 
an analytic tool.  
McGuire’s Communication/Persuasion Matrix 
 McGuire, a Yale psychology professor, created a theoretical model that 
explains the range of audience responses to the mass media’s messages. In direct 
contraction of the magic bullet theory’s assumption of a single uniform 
interpretation of media messages by the audience, he developed a 
communication/persuasion matrix consisting of a system of inputs and outputs 
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that describes how audience responses to mass media vary based on 
characteristics of the communication. In the matrix, the input variables are the 
column headings and the outputs are the row headings; each cell contains the 
relationship between the two, as determined through empirical research or 
theorizing (McGuire, 2000). 
 There are five types of input communication variables: source (who says 
it), message (what is said), channel (via which medium e.g. newspaper), receiver 
(to whom), and target (aimed at changing what) (McGuire, 2000). The output 
steps are the twelve possible outcomes of being persuaded by the communication, 
such as message exposure, attention, liking, comprehension, skill acquisition, 
yielding, memory storage and agreement, information search and retrieval, 
deciding, behaving, reinforcement, and postbehavioral consolidation (Bull, 2001). 
These output steps precede behavior change, the goal of the communication 
campaign (Glik, 2007). McGuire recommends success at each output step in order 
to optimize the likelihood of behavior change; he attributes many communication 
failures to focusing on only one or two of the output steps and neglect of the 
others (Bull, 2001).   
 McGuire’s communication/persuasion matrix is a classic theoretical model 
within the discipline of health promotion and communication; practitioners must 
optimize the input variables in order to plan a communication campaign that 
persuades people to change health behaviors (Glik, 2007). For example, while 
designing the message, there are many factors to consider. The message category, 
one of the five categories of input variables, can be subdivided into categories 
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such as type of argument, inclusions and omissions, ordering, extremity, and 
style; the style subcategory can be further divided into variables such as intensity, 
complexity, humor, and literalness vs. figurative language (McGuire, 2000). All 
of these factors within the message category, combined with the other categories, 
contribute to the overall success of the persuasive communication.  
 Using McGuire’s model of inputs and outputs as an analytical framework, 
Bull and colleagues (2001) evaluated the impact of three types of printed health 
education materials (HEMs) about weight loss on an audience of 198 overweight 
adults who were interviewed and who completed questionnaires before and after 
viewing the HEMs (Bull, Holt, Kreuter, Clark, and Scharff, 2001). They assessed 
psychosocial, demographic, and physical characteristics of the receivers; 
psychosocial characteristics included the participants’ weight locus of control, 
readiness to lose weight, level of self-efficacy, and existing knowledge of the 
information in the HEMs, and age, gender, level of information, and BMI, as 
calculated from measured height and weight, were recorded as well. Other inputs 
that were assessed included the preparedness to read printed materials (a channel 
factor), the perceived credibility and attractiveness of the HEMs (source factors), 
and the perceived degree of informativeness, encouragement, usefulness, and 
applicability to one’s life of the HEM (message factors) . Researchers measured 
ten output variables: exposure, attention, liking, understanding, skill-
acquisition/learning how, yielding, memory storage/agreement, information 
search and retrieval, deciding, and behaving. They reported that early output steps 
(attention, liking, and understanding) and the mediating output steps (recalling, 
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keeping, and rereading HEMs) were associated with attractiveness of the 
materials, encouragement, level of information, and application to one’s life. 
Behavior change was more likely among participants who had higher self-efficacy 
and had received customized HEMs. They concluded that not all output steps 
were necessary for behavior change and that the HEMs perceived applicability to 
one’s life was the most important input variable for predicting the success of the 
HEM (Bull et al., 2001).  
 Houts and colleagues (2006) reviewed nineteen peer-reviewed health 
education studies which examined the role of pictures in health communications 
(an input variable which falls into the category of message factors), and assessed 
attention, comprehension, recall, and adherence which align with the output steps, 
attention, comprehension, memory, and acting on the decision (Houts, Doak, 
Doak, and Loscalzo, 2006). Health communication topics included wound care, 
instructions on when to take medicine, and breast self-examination. Results 
showed that pictures do have significant potential to improve the effectiveness of 
the health communication, especially among a low-literacy population, but 
interpretations of the messages can vary according to many factors such as 
cultural differences. They recommend evaluating the success of the 
communications materials through follow-up interviews, in a clinical setting, that 
assess the outcomes of attention, comprehension, memory, and acting on the 
decision (Houts et al., 2006).  
 Kelly and colleagues (2009) administered a randomized telephone survey 
among five underserved zip codes to assess the input characteristics of their target 
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population during the design phase of a public health campaign to encourage 
awareness of cancer family history and to promote usage of an Internet-based 
cancer risk assessment tool (Kelly, Sturm, Kemp, Holland, and Ferketich, 2009). 
They developed a system of measuring receiver variables (e.g., demographics, 
worry), source variables (e.g., credibility, attractiveness), channel variables (e.g., 
modality, efficacy), message variables (e.g., type of appeal, discrepancy from 
initial position), destination variables (e.g., attitude change vs. behavior change, 
immediate vs. delayed). Results regarding receiver characteristics showed that 
race (African American vs. Others) resulted in few statistically significant 
differences and that a lower level of education was associated with a lower 
likelihood to seek information from the Internet. The most preferred source of 
information was a family member. All channels were rated highly, especially the 
Cancer Information Service and public libraries. Regarding the message factors, 
they found that there was little need to promote the importance of knowing one’s 
cancer family history, as most already agreed, but that designing a message to 
encourage action, such as sharing cancer family history with a physician, was 
more appropriate. Results regarding destination factors showed the need to 
promote behaviors to assess cancer risk such as seeking computerized risk 
assessment tools (Kelly et al., 2009).   
Diffusion of Innovation 
 With the publication of his classic 1962 book Diffusion of Innovations, 
Everett Rogers popularized the diffusion of innovation theory to explain how new 
ideas spread throughout society. Diffusion is a specialized form of 
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communication because the content of the messages is perceived as new and 
therefore carries a degree of risk, or uncertainty (Rogers, 2002). There are four 
stages in adopting an innovation: knowledge of the innovation, persuasive 
communication about the innovation, the decision to adopt or reject the 
innovation, and confirming the acceptance of the innovation. An innovation is 
more readily diffusible if is compatible with existing beliefs, easy to try, 
observable, is perceived as low risk, and offers relative advantages to the status 
quo (Smith, 2004). 
 One can classify the population in terms of readiness to accept new ideas: 
first are the innovators (2.5 %), then the early majority (13.5%), the late majority 
(34%), the late adopters (34%), and finally, the laggards (16%) (Rogers, 2002). A 
successful community nutrition program that increased the practice of exclusive 
breastfeeding for the first six months among mothers in Ghana demonstrated the 
classic early adopters/late adopters pattern of adopting innovation (Smith, 2004). 
The diffusion of exclusive breastfeeding spread with ease throughout the social 
group because it met the ideals of ‘‘compatibility, trialability, observability, not 
being too risky, and relative advantage” (Smith, 2004).   
 Vermeer and colleagues (2009) conducted a qualitative study in the 
Netherlands using the diffusion of innovation model to assess the feasibility of a 
variety of interventions aimed at reducing portion sizes of foods, e.g. offering a 
self-portioning option in which the customer selected the portion size of the food 
(Vermeer, Steenhuis, and Seidell, 2009). They held semi-structured hour-long 
interviews with 22 individuals, using an interview guide that explored perceptions 
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of the relative advantage, risks, complexity, and communicability of each portion-
size intervention (Vermeer et al., 2009).   
 Nanney and colleagues  (2007) conducted a survey of 675 educators from 
48 states to evaluate their awareness of, and subsequent adoption of, a nationally 
disseminated dietary curriculum called High Five, Low Fat (H5LF) (Nanney, 
Haaire-Joshu, Brownson, Kostele, Stephen, and Elliott, 2007). The survey asked 
about key factors influencing the adoption of a dietary curriculum: time required, 
communicability, complexity, risk commitment, complexity, relative advantage, 
compatibility, relative advantage, and impact on social relations (Nanney et al., 
2007). Compared to non-adopters of the curriculum, adopters of the curriculum 
were almost 8 times more likely to identify training time as a factor influencing 
adoption and almost 7 times more likely to identify the CD training method as a 
factor influencing adoption.   
  Rogers emphasizes the effectiveness of the mass media in the first stage 
of the process, spreading information about the innovation (Servaes, 1995). 
Barker (2004) described a successful program to increase vitamin A status 
through food-based programs in Nepal, where health issues due to vitamin A 
deficiencies contribute to the country’s high infant and mortality rate.  The 
Market Access for Rural Development program focused on promoting fruit and 
vegetable crops and used nutrition demonstration households with kitchen 
gardens to increase production and consumption of foods rich in vitamin A. The 
number of households with kitchen gardens increased by tenfold (from fewer than 
100 to 1131) within a year of the launch of a communications campaign that 
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educated women about the risks of vitamin A deficiencies and the benefits of 
cultivating kitchen gardens with foods rich in vitamin A. The program’s success 
was in part due to an increased focus on promoting awareness of the program 
itself and providing information on its benefits to the target families (Barker, 
2004) 
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Section 4 
Health Behavior Theories 
  Rich in theory-based interventions, the research literature about health 
behavior change focuses on why and how individuals and communities adopt new 
health behaviors. This section reviews the health belief model, social cognitive 
theory, the transtheoretical model, and hope theory. Within each of these 
theoretical models, the mass media plays a role in influencing consumers in the 
arena of decisions about health, nutrition, and usage of weight loss products. 
According to the health belief model, the content of media messages can induce 
dieting behavior by increasing perceptions of susceptibility and severity of obesity 
and decreasing the perceived barriers to change.  Social cognitive theory 
acknowledges the interactive influence of media and society on creating the 
media agenda about nutrition-related topics. The transtheoretical model shows 
that media messages about weight loss may resonate with people contemplating 
change.  In hope theory, individual and collective hopes for weight loss can be 
inspired by media campaigns.  
Health Belief Model 
 For over half a century, the health belief model has provided a useful set 
of principles for designing and evaluating health interventions. The theory 
explains an individual’s likelihood of making a behavioral change according to a 
subjective cost-benefit analysis that takes into account the individual’s perceived 
susceptibility to an illness, perceived severity of the illness, perceived benefits of 
the new health behavior, and the perceived barriers to executing the new health 
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behavior (Becker, Maiman, Kirscht, Haefner, and Drachman, 1977). Perceived 
susceptibility, or vulnerability, to a specific negative health outcome is a 
perception of risk that varies among individuals. The perception of a disease’s 
severity, with respect to medical, social, and financial consequences, differs 
among individuals as well.  An individual will adopt a new health behavior if the 
perceived benefits of the action outweigh the perceived barriers, such as financial 
costs or inconvenience (Janz and Becker 1984 p. 2). While not explicitly 
mentioned in the health belief model, demographic and structural variables 
influence health behavior as well; for example, socioeconomic status and 
educational level may affect perceptions of susceptibility to and severity of 
disease as well as perceptions of benefits and barriers (Champion and Skinner, 
2008).     
 In addition to the four classic constructs, a key element of the health belief 
model is the cue to action, which is a stimulus to the health behavior; cues to 
action are assumed to be widely available in the environment (Becker et al., 
1977). Mass media messages encouraging the consumption of fruits and 
vegetables, discouraging sedentary behavior, and promoting weight loss are 
examples of cues to action. Insufficient attention, however, has been given to the 
role of cues to action in the health behavior change research literature (Johnson 
and Meischke,1993).  
 Ogden and Hills (2011) recognized the importance of cues to action as 
they explored themes from the health belief model during qualitative interviews 
with 34 adults who had maintained successful long-term  (> 3 years) behavioral 
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changes in weight through diet and exercise (n = 24) or stopped smoking (n = 10).  
They reported that life crises such as relationship break-ups and adverse health 
events served as triggers (similar to cues to action) for behavioral change in the 
short term. For example, one subject said that having his fourth heart attack at the 
age of 37 caused him to commit to taking orlistat to help him lose weight .  They 
found that one condition for sustaining long-term behavioral change was the 
belief in a connection between the individual’s behavior and resolving the health 
issue; this concept is related to the construct of perceived benefits of the health 
behavior in the health belief model (Ogden and Hills, 2011).   
 The original health belief model was based on taking action to avoid 
disease, but since then, the motives for changing health behavior have been 
expanded to include achieving better health, improved body image and greater 
social acceptance, and avoiding or treating obesity (Becker et al., 1977). Key 
theoretical assumptions include the importance of the individual’s internal locus 
of control over behavioral change rather than on environmental or community 
factors and the idea that health is a highly-valued goal (Janz and Becker, 1984). 
Another underlying premise is that cognitive processing is responsible for 
decision-making related to health behavior (Glik, 2007). 
 There is debate in the literature about the role of self-efficacy in initiating 
health behavior change. Rosenstock, Strecher, and Becker (1988) proposed 
adding the concept of self-efficacy, or competence at performing the intended 
behavior, as a distinct construct of the health-belief model because enacting long-
term behavioral change, such as modifying dietary habits, requires an individual 
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to have high self-efficacy.  Other researchers, such as Janz and Becker, include 
self-efficacy in the category of perceived barriers (Janz and Becker, 1984).   
 The health belief model traditionally looks at initiating behavior change in 
the short term. Sun and colleagues  (2007)conducted a community-based 
intervention promoting the consumption of iron-fortified soy sauce through mass 
media and interpersonal communication among Chinese women at risk of iron-
deficiency anemia; the outcome measures were based on the concepts of the 
health belief model (Sun, Guo, Wang, and Sun, 2007).  Both the control and 
intervention groups in the rural (n = 193) and urban (n= 179) populations were 
exposed to newspaper and television media messages about iron-fortified soy 
sauce.  The intervention groups also received nutrition and health lectures and 
health counseling about iron deficiency, calendars containing information about 
iron-fortified soy sauce, and gift bags of iron-fortified soy sauce.  Before and after 
the intervention, researchers administered a questionnaire, using Likert-type 
scales, which included items designed to assess the subjects’ perceived benefits of 
using iron-fortified soy sauce and perceived barriers (for example, a fear of the 
taste of dishes being altered). Researchers concluded that the intervention was 
successful because knowledge, purchase, and use of iron-fortified soy sauce 
increased and because perceptions of iron-fortified soy sauce were improved, as 
measured by the increase in scores regarding perceived benefits and the decrease 
in scores regarding perceived barriers (Sun et al., 2007).   
 Petrovici and Ritson (2006) utilized the health belief model to predict 
dietary health preventive behavior in an at-risk Romanian population.  Results of 
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administering face-to-face questionnaires to 485 adults showed that health 
motivation, perceived diet effectiveness, and knowledge about nutrition were 
significant factors in predicting positive behaviors related to diet; they were 
surprised to find that the perceived threat of disease had a negative rather than the 
expected positive association with dietary health preventive behavior. They 
concluded that future health interventions should clarify the connection between 
health behavior and outcomes in order to improve perceived benefits among the 
public (Petrovici and Ritson, 2006).     
 The health belief model lends itself well to qualitative, exploratory 
research.  Liou and Bauer (2007) used the concepts of the health belief model, 
among other health behavior theories, to design an interview guide used in a study 
of dietary determinants in obesity.  They conducted semi-structured interviews 
with 40 Chinese American adults between the ages of 18 and 30 in the New York 
City metropolitan area.  Interview questions included explicit questions about the 
benefits of a healthier diet and barriers to eating healthfully.  To assess perceived 
severity, they asked: “What are some health consequences of obesity?”  They 
investigated the theme of perceived susceptibility through questions such as: “Do 
you think obesity is a health concern for Chinese Americans? Do you personally 
feel susceptible to obesity”? What are the major causes of obesity in Chinese 
Americans? Are US-born or foreign-born individuals more prone to this 
condition?”.  They found that the perceived benefits of eating healthfully and 
being physically active included having a decreased risk of illness and a longer 
life span.  The perceived barriers were the availability of convenient fast food, 
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mass media advertising, the lack of available and affordable healthy foods, lack of 
social support for healthful eating, and taste preferences for foods high in fat and 
refined carbohydrates.  They found that sixty percent of the participants felt 
susceptible to obesity.  They identified peer support and mass media as cues to 
action.  Environmental factors were perceived to have the strongest influence on 
food behavior and risk of obesity. They determined that social support is 
necessary for maintaining positive health behaviors (Liou and Bauer, 2007). 
 In the health belief model, the mass media can play an important role in 
communicating the benefits of a health behavior, minimizing barriers, and 
promoting perceptions of susceptibility and severity, in addition to presenting 
cues to action. Larsson and colleagues (2004) incorporated the health belief model 
into a questionnaire sent to an intervention group (n = 261) and a comparison 
group (n = 206) to evaluate a health intervention that promoted the usage of 
emergency contraceptive pills using several channels, including a mass media 
campaign that spread information through advertising in the local newspaper and 
student newspaper, mounting posters in universities and student clubs and 
advertising on buses (Larsson, Eurenius, Westerling, and Tyde, 2004). They 
concluded that the intervention was successful at increasing the likelihood of 
taking action if necessary (using emergency contraceptive pills) and that 
perceived barriers of side effects declined over time in the intervention group.   
 In a review of forty-six studies based on the health belief model, 
researchers reported that perceived barriers is the construct that had the strongest 
correlation with the specific health behavior being studied (Janz and Becker, 
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1984). This result may be attributed in part to the relative simplicity of 
operationalizing this construct, whereas perceived susceptibility, perceived 
severity and perceived benefits may be more difficult variables to operationalize, 
or to standardize across research studies.  A limitation of the health belief model 
is that a standardized scale for each construct, in relation to a specific health 
behavior being studied (e.g. getting a mammography vs. a colonoscopy), and in 
relation to a specific target population (e.g. segmented by race, age, 
socioeconomic status, and gender), does not generally exist in the research 
literature (Champion and Skinner, 2008). The predictive power of the health 
belief model depends on the accuracy of operationalizing and measuring each 
construct; therefore, the health belief model’s strengths may lie in explaining 
rather than predicting.  It was created, after all, by a group of social psychologists 
at the U.S. Public Health Service in the 1950s in order to make sense of the 
public’s failure to comply with medical recommendations to prevent disease or 
obtain screening tests for early detection of disease (Janz and Becker, 1984). 
 The health belief model may be more powerful in explaining some health 
behaviors than others.  While researchers Johnson and Meischke acknowledge the 
value in the model’s applicability to preventive health behavior, they did not find 
it to be useful when applied to information-seeking about breast cancer 
mammography screening in magazines (Johnson and Meichke, 1993).  They 
conducted telephone interviews with 366 women over the age of 35 and asked 
questions about health-related factors such as demographics, direct experience 
with breast cancer, salience of breast cancer information (related to perceived 
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susceptibility and perceived severity), and beliefs about medical procedures 
related to cancer in addition to their information-seeking behavior. They 
concluded that for this particular health behavior, information carrier factors (such 
as editorial tone) are more important than health-related factors; the health belief 
model traditionally does not address the nuances of information delivery.  They 
found the “two-step flow” communication theory, with magazine editors as the 
opinion leaders and readers as the followers, to be more relevant to information-
seeking health behavior than any health behavior theories (Johnson and Meischke, 
1993). 
 There are many related concepts among the health belief model and other 
health behavior change theories.  They are perhaps most useful in combination 
rather than in isolation. The inherent differences in the range of health behaviors 
make it very difficult for one theory to fit all of them.  Health behaviors do not 
exist in isolation from other non-health behaviors either.  Other theoretical 
models, as in the Johnson and Meischke study, may be more appropriate in some 
cases.   
Social Cognitive Theory 
 Social cognitive theory is the most common foundation for weight 
management interventions and is frequently used to create physical activity 
interventions (Palmeira, Teixeira, Branco, Martins, Minderico, Barata, Serpa, and 
Sardinha,  2007). In social cognitive theory, human behavior arises from a 
dynamic interaction of internal, behavioral, and environmental factors that 
influence each other bi-directionally (Bandura, 2001).  Social cognitive theory 
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evolved from social learning theory, which posits that expectancies and perceived 
incentives guide behavior changes (Rosenstock, 1988).  When concepts about 
human cognition and processing were integrated into social learning theory, it was 
renamed as social cognitive theory (Viswanath, 2008).  Social cognitive theory is 
based on the principle of reciprocal determinism, in which people and their 
environments are continually shaping and changing each other.  Neither solely 
dependent on environment, nor predestined to act according only to internal 
beliefs, individuals are “self-organizing, proactive, self-reflecting, and self-
regulating” (Bandura, 2001).  
 The capacity for observational learning is a key component of social 
cognitive theory, in which individuals can learn, not only from their own trial and 
error experiences, but also through observing the behavior and outcomes of others 
(Young and Cline, 2005).  There are four processes involved in observational 
learning: attention, retention, behavioral production, and motivation (Bandura, 
2001).  Young and Cline (2005) utilized the concepts of observational learning in 
their study of 225 direct-to-consumer prescription drug advertisements in 18 
consumer magazines; they found that the advertisements contained visual and 
textual cues (e.g. medical rewards, gaining freedom, and achieving normality in 
one’s life) to motivate consumers to communicate with their health-care providers 
about usage of the advertised drug.   
 According to Bandura, “health is a social matter, not just an individual one” 
(Bandura, 2004). While environmental factors influence behavior, people’s 
behavior shapes social systems (Bandura, 2001). Sustaining health behavior 
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change, therefore, requires individuals to change their environment to support the 
new behavior.   
 The mass media is a powerful environmental determinant of health 
behavior.  Media often contributes in negative ways to reinforcing unhealthy 
behaviors, however. In order to improve the collective health status of society, the 
mass media must be transformed into a force that facilitates positive health 
behaviors such as achieving and maintaining a healthy weight, eating a balanced 
diet that includes vegetables and fruits, getting regular physical activity, and 
abstaining from smoking.  
 In the social cognitive view, mass media has two main modes of influence. 
In the direct pathway, media can provide information about health behavior 
change, demonstrate social models of change, offer motivations, and provide 
strategies for change, e.g. by covering nutrition and health issues and by 
influencing consumers’ purchasing decisions (Bandura, 2004). 
 In the socially mediated pathway, the media helps individuals connect 
with social networks and community settings, which offer interpersonal social 
support, guidance, and motivation for health behavior change (Bandura, 2004).  
Critical evaluations of the outcomes of public health campaigns that utilize the 
media are essential (Noar, 2006).  
 Through the process of agenda-setting, “people are producers as well as 
products of social systems” (Bandura, 2001). Campo and colleagues (2009) 
applied social cognitive theory to their analysis of newspaper coverage of articles 
about college binge-drinking (Campo, Askelson, Mastin, and Slonske, 2009).  
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They examined strategies for addressing college-binge drinking in 255 articles 
from 32 major U.S. publications over a period of ten years between 1997 and 
2006. They found that while there was a mix of individual-focused and 
environment-focused strategies for addressing college binge-drinking, there was a 
general lack of coverage of the issue and a lack of evidence-based strategies being 
presented in favor of describing actual health interventions which were not 
established based on scientific evidence. They identified a need for media 
advocacy, which involves working directly with the media to frame college-binge 
drinking as a public health issue. Media advocacy goals would include placing 
college-binge drinking on the public health agenda and emphasizing the need for 
evidence-based solutions to be incorporated into practice (Campo et al., 2009). 
 Mass media communication can affect perceived norms, influence 
individual attitudes about the health behavior, enhance perceived susceptibility to 
an illness, and increase self-efficacy or confidence about taking action, which in 
turn affect health behaviors (Randolph, 2004). Editorial content of women’s 
magazines is a highly influential force on setting social norms regarding women’s 
health behaviors. Cho and colleagues (2010) analyzed 250 articles about tanning 
and skin cancer risk and prevention from eight popular women’s magazines from 
1997 to 2006 and reported that the focus was primarily on skin cancer prevention 
and the adverse consequences of suntanning; however, there is a need for more 
coverage of consequences of tanning bed use and for more recommendations to 
use multiple methods of sun protection in addition to sunscreen, such as staying in 
the shade and wearing protective clothing (Cho, Hall, Kosmoski, Fox, Mastin, 
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2010). Improving the quality of health-related messages in women’s magazines 
would contribute to social norms that promote positive health behaviors.   
  Self-efficacy, the belief that an individual is capable of taking action, is a 
key social cognitive construct which is essential for initiating and sustaining 
behavior change (Bandura, 2004).  Palmeira and colleagues (2007) utilized social 
cognitive theory and three other health behavior change theories to predict short-
term weight loss among 142 overweight and obese women participating in a 16-
week weight loss intervention that included weekly group education sessions that 
included content on exercise, nutrition, and behavior modification; results showed 
that self-efficacy regarding weight management, as measured by a questionnaire, 
was the strongest predictor of weight loss (Palmeira et al., 2007).  
 One effective way of increasing self-efficacy beliefs is through vicarious 
experiences gained through social modeling (Bandura, 1998).  The individual 
identifies with social models who are similar to themselves and who have taken 
action to change their health behavior.  Social models provide strategies for 
overcoming challenges presented in the environment.  The mass media can 
present positive social modeling for the purpose of health promotion.  Conversely, 
negative social modeling in the media can adversely affect health promotion 
efforts. Using rhetorical and content analysis, Dutta and Boyd (2007) examined 
depictions of the “smoking man” in advertising and editorial content in three 
popular men’s magazines and found that men who smoked were portrayed as 
independent, mysterious, sensual, and belonging to another place; these images of 
smoking men embody the masculine ideal of rugged individualism.  They 
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recommend creating media content that specifically counteracts these images 
(Dutta and Boyd, 2007).   
 Mass media messages should focus on both individual and environmental 
changes to optimize the power of reciprocal determinism in reinforcing healthy 
behaviors. Campo and Mastin (2004) studied 406 articles addressing overweight 
and obesity in African-American women’s magazines and mainstream women’s 
magazines from 1984 – 2004; in their content analysis, they found 60 strategies 
for preventing and treating overweight and obesity and that the focus of these 
strategies was overwhelmingly on individual behavior rather than on 
environmental factors. Individual behavior-focused changes, such as participating 
in moderate or regular exercise and eating a balanced diet or fewer calories, 
comprised 83.3% of the strategies.  Cognitive or affective strategies related to 
personal change, such as increasing self-acceptance, were less common, at 21.7%.  
Environmental changes, such as getting support from family and friends and 
removing cues that trigger eating, made up just 6.7% of the strategies. They 
concluded that in order to improve rates of overweight and obesity in society, 
public health practitioners should advocate for mass media content that focuses 
more on changes that can be made in the environment. They also found that 
strategies related to self-efficacy, were presented much less frequently in African-
American women’s magazines than in mainstream women’s magazines (Campo 
and Mastin, 2004).   
 The social cognitive view of mass media is empowering because in the 
tradition of reciprocal determinism, people are capable of creating a media 
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environment of their own choosing.  The mass media have the potential to have a 
broad impact on public health issues. Studying the media’s effects on health 
attitudes and behaviors is a critical first step to designing a media environment 
that promotes the collective health of society.  
Transtheoretical Model 
 Prochaska and DiClemente (1977) developed the transtheoretical model to 
explain the process of behavioral change in the context of smoking cessation. 
Also known as the stages of change model, this popular health behavior theory 
has been applied to interventions focusing on dietary change, physical activity, 
and the cessation of alcohol and drug use (Resnicow, McCarty, and Baranowski, 
2003).  For example, public health practitioners utilized the transtheoretical model 
to design the National 5 A Day campaign, targeted to a broad audience of 
Americans in various modes of readiness to change, which promoted awareness 
of the benefits of higher fruit and vegetable intake and taught skills for increasing 
fruit and vegetable intake through community-based channels and mass media 
(Heimendinger, Van Duyn, Chapelsky, Foerster, and Stables, 1996). 
 While researchers have found the model to be useful for classifying 
individuals into stages of readiness for dietary change (specifically in studies that 
explore low fruit and vegetable intake), it has been used less successfully to 
predict behavior change based on the stage of the individual (Resnicow et al. 
2003). The conceptual distinction between increasing fruit and vegetable intake 
and quitting smoking could be the reason that the transtheoretical model is a 
better fit for nutrition behaviors that are more similar to the addictive behavior of 
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quitting smoking, such as eliminating alcoholic beverages, rather than modifying 
one’s diet. 
 There are two dimensions of the transtheoretical model: 1) the six 
sequential stages of behavior change, delineated according to pre-defined time 
periods, and 2) a group of constructs that describe the cognitions and behaviors 
that characterize moving through the stages of change (Palmeira et al., 2007). The 
stages of behavior change are precontemplation, contemplation, preparation, 
action, maintenance, and termination. An individual who is a precontemplator is 
unmotivated to change and has no intention to change within the next six months, 
whereas an individual who is a contemplator has resolved to take action within 
the next six months. An individual in the preparation stage intends to change 
within the next 30 days and has made some behavior changes that indicate 
commitment to taking action. In the action stage, the individual’s behavior 
changes have existed for less than six months. The maintenance stage requires the 
new behavior to have persisted for over six months. Regression through the first 
five stages is possible. An individual in the termination stage, however, has 
successfully adopted the behavior change and will not regress to a previous stage 
(Prochaska, Redding and Evers, 2008).   
 The constructs of the transtheoretical model include the 10 processes of 
consciousness-raising, dramatic relief, self-reevaluation, environmental 
reevaluation, self-liberation, helping relationships, counterconditioning, 
reinforcement management, stimulus control, and social liberation; research 
demonstrates that the adoption of these activities indicates readiness to progress 
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through the stages of change.  (Prochaska et al.k 2005).  Consciousness-raising, 
for example, is promoting awareness of the causes, effects, and solutions to a 
problem behavior among the audience. Effectively-designed mass media 
campaigns can facilitate a receptive population to move from the 
precontemplative and contemplative stages into the preparation or action stages. 
 Two additional concepts are important in the transtheoretical model. 
Decisional balance, the weighing of the pros and cons of the behavior change 
being considered, reflects the individual’s current stage. A precontemplator is 
more aware of the cons than the pros of the behavior, a contemplator is aware of 
the pros and cons of change but is ambivalent, and someone in the preparation 
stage focuses more on the pros than the cons. Self-efficacy, the individual’s belief 
in being able to perform the new behavior, is low in the precontemplation and 
contemplation stages and increases as the individual prepares and takes action; an 
individual in the termination stage has the highest level of self-efficacy (Palmeira 
et al., 2007). 
 In a study that raised questions about the theoretical significance of the 
first three stages of change, Resnicow and colleagues (2003) examined the 
relationship between the stage of change assessed at baseline and the behavioral 
and psychosocial outcomes one year later in a sample of African-American adults 
who participated in the Eat for Life Trial, a church-based intervention intended to 
increase fruit and vegetable intake.  There were 14 churches and subjects were 
classified as being in precontemplation (n=105), contemplation (n=19), 
preparation (n=353), action (n=105), and maintenance (n=236).  They reported 
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that 85% of precontemplators moved ahead one stage, whereas only 33% of 
individuals who were in the preparation stage moved ahead and 15% of them 
regressed.  This result was surprising because according to the transtheoretical 
model, precontemplators should have demonstrated less behavior change than the 
individuals in the preparation stage. They concluded that the first three stages of 
change are not useful for predicting change in increasing fruit and vegetable 
intake and suggested that the time frames of 30 days and six months are less 
meaningful for dietary change than for smoking cessation, an addictive behavior 
whose ultimate goal is abstinence. They recommended not using stage-based 
tailoring for each of the first three stages and instead combining them into one 
‘preaction’ stage (Resnicow et al., 2003).  
 Another study demonstrated that the act of enrolling in a weight 
management program does not guarantee that individuals are in the preparation or 
action stages.  Krummel and colleagues (2004) evaluated factors related to the 
transtheoretical model in behaviors relevant to weight management.  Subjects 
were enrolled in a weight management program called the Mothers’ Overweight 
Management Study (MOMS) and recruited from a population of adult women 
who had given birth to a child within the past two years and were participants in 
the Special Supplemental Nutrition Program for Women, Infants, and Children 
(WIC) (Krummel, Semmens, Boury, Gordon, and Larkin 2004).  Researchers 
assessed the subjects’ responses to statements about their performance of four 
weight management behaviors in the context of the time frames specified by the 
transtheoretical model: weight loss, choosing not to eat high-fat foods, eating 
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fiber-rich foods, and exercising 3 times per week.  They used previously validated 
instruments to assess decisional balance, psychosocial characteristics, and 
depressive symptoms.  Results showed that 17% - 30% of the participants were in 
the precontemplation and contemplation stages, which was a higher proportion 
that expected, and only 55% of the participants were in the action stage, which 
was far less than anticipated given that the participants were enrolled in a weight-
management program. They concluded that women may not have sufficient 
weight-management behavior skills and that enrollment in a weight-management 
program is not necessarily an indicator of readiness to change (Krummel et al., 
2004).   
 One of the constructs of the transtheoretical model, consciousness-raising, 
is particularly conducive to influence by the mass media. Renger, Steinfelt, and 
Lazarus (2002) reported positive results from a community-based television and 
worksite media campaign which had the goal of raising consciousness among 
physically inactive adults aged 30-64 in Yuma, Arizona about the benefits of 
regular physical activity. The media messages, in the form of 30-section 
television public service announcements, comic strips in worksite newsletters, and 
worksite posters were designed to increase self-efficacy and focused on benefits 
and barriers.  Researchers used telephone interviews and written surveys at 
schools and businesses to evaluate the impact of the intervention in the 
community. They found that the intervention resulted in actual behavior change 
and increased the level of physical activity among the targeted group of Yuma 
residents.  They acknowledge that this finding contrasts with existing evidence 
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that consciousness-raising is insufficient to cause behavior change and suggested 
that the local community focus of the tailored media messages may have 
contributed to the effectiveness at producing behavior change.  There was no 
control group in this study, but the rest of Arizona reported increased numbers of 
sedentary individuals while the number of sedentary people decreased in Yuma 
(Renger et al., 2002).  
 Applying the transtheoretical model to initiating regular physical activity 
has been effective for reaching people in the contemplative stage.  Reger and 
colleagues (2002) created  a physical activity intervention targeted at sedentary 
adults aged 50 to 65 that successfully increased the proportion of the group that 
met the standard for regular moderate-intensity walking by 23%  and facilitated 
progression to the next transtheoretical model stage (Reger, Cooper, Booth-
Butterfield, Smith, Bauman, Wootan, Middlestadt, Marcus, and Greer, 2002).  
The eight-week media-based campaign utilized multiple channels to distribute the 
message to walk at least 30 minutes at least five days per week. They designed a 
mass media campaign involving paid advertising in local newspapers, radio, and 
television and an interactive website and launched public relations activities at 
community sites that generated television and radio coverage. They trained local 
health professionals to give presentations about walking and physical activity in 
the community.  To assess the impact of the intervention, researchers conducted 
interviews of individuals walking at five sites for two hours daily for a week both 
prior to the intervention and after the intervention. They also collected data using 
a telephone survey questionnaire before and after the intervention. They used a 
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non-intervention group in a similar community for comparison as well. They 
concluded that the campaign had a positive effect on the desired behavior change 
of initiating walking and produced positive changes in perceived control and 
intention (Reger et al., 2002).    
  While encouraging an at-risk population to move into the action stage is 
extremely difficult using traditional action-oriented behavior interventions, a 
stage-based intervention should be more successful (Prochaska, Redding, and 
Evers, 2005); causing dietary change, however, involves many barriers.  Findings 
from a randomized crossover intervention targeted at recipients of Maryland’s 
WIC 5-A-Day Promotion Program, which was designed using principles of the 
transtheoretical model, indicated success at meeting the goal of increasing fruit 
and vegetable servings by half a serving per day among intervention participants; 
mean daily consumption increased by 0.56 + 0.11 servings in the intervention 
group and by 0.13 + 0.07 in the control group (P = .002) (Havas, 1998).  The goal 
of half a serving was considered realistic according to community nutrition 
intervention standards. The multi-faceted program included nutrition education 
sessions led by peer educators, printed materials such as a photonovella and a 
booklet of recipes by participants, and direct mail. Results showed, however, that 
the intervention generated movement in the stages of change only among Whites 
and participants with a high school education. While all of the peer educators 
were Black and had a high school or general equivalency diploma, these 
characteristics did not help to motivate Black participants and participants with 
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less education. This obstacle is an opportunity for further research on how the 
intervention can be adapted to meet the needs of more participants. (Havas, 1998).   
 Similar to media communication encouraging physical activity for 
sedentary individuals, media messages about weight loss may resonate with 
people in various stages of change who need to eliminate lifestyle behaviors that 
cause excessive weight gain. Well-designed media messages may influence 
precontemplators to become contemplators, contemplators to progress to the 
preparation stage and for individuals in the preparation stage to advance to the 
action stage. For example, contemplators demonstrating ambivalence and a lack 
of commitment to act in the near future may be inspired by media messages about 
the benefits of avoiding foods high in saturated fat.  While the behavior of eating 
high-fat foods is not conceptually equal to smoking, this particular behavior has 
the potential to be extinguished in much the same way by applying the time 
frames of 30 days and six months to the behavior change and substituting the goal 
of consuming these foods rarely instead of setting a goal of abstinence. 
 
Hope Theory 
 The field of health psychology offers many opportunities to deepen the 
understanding of how hope may be leveraged to improve health outcomes. 
Research findings have found connections between hope and psychological, 
physiological, cognitive, and behavioral benefits  (Drahos, 2004). Within the 
context of clinical practice in Western medicine, researchers have been exploring 
the association between patients’ hopes about their own treatment outcomes, and 
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their resulting attitudes and behaviors (Leung, Silvius, Pimlott, Dalziel, and 
Drummond, 2009).  
 While hope can uplift, it can also endanger; patients who are 
unrealistically hopeful about their condition may forgo beneficial curative or 
palliative treatments (Schneiderman, 2005). Marketers of diet products are 
frequently accused of being in the “hope business” by abusing consumers’ hopes 
for transforming their lives via weight loss (Drahos, 2004). Public hope can be 
manipulated to the detriment of millions of people, as in the case of the World 
Trade Organization’s 1993 Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS). This international trade agreement regarding intellectual 
property laws enabled large overseas pharmaceutical companies to take out 
patents on drugs in developing countries, thereby preventing the developing 
country’s own pharmaceutical industry from producing cheaper generic versions. 
Developing countries signed TRIPS because they hoped, unrealistically, that they 
would benefit from the patent laws as exporters of international patents someday; 
at the time, however, only the multinationals profited from the arrangement.  A 
better solution that would have served their own interests would have been to 
create a coalition of developing countries that would resist the trade sanctions 
being placed on them by developed countries (chiefly, the United States). In 
South Africa, TRIPS effectively removed access to affordable AIDS antiretroviral 
medications for the poor that would have prevented the transmission of HIV 
between mothers and babies (Drahos, 2004).   
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 Psychiatrists and psychologists began to study hope in the late 1950s as 
they began exploring the construct ‘positive expectations for goal attainment’ 
(Snyder, 2000). Hope has a multitude of definitions: “a cognitive attitude, an 
emotion, a disposition, and even a process or activity” (McGeer, 2004).  In one 
cognitive approach to hope, Leung and colleagues (2009) distinguished between 
hopes and expectations; they defined expectations as an estimation of the most 
likely outcomes, and characterized hopes as an estimation of the most desired 
outcomes, without regard for the probability of the event’s occurrence (Leung et 
al., 2009).  
 According to Snyder’s classic model, hope is “a positive motivational 
state that is based on an interactively derived sense of successful (a) agency (goal-
directed energy), and (b) pathways (planning to meet goals)” (Snyder, 2002). This 
theory focuses on cognitive processes involved in experiencing hope; rather than 
viewing hope itself as the emotion, the individual experiences emotional 
responses as a result of the unattainment or attainment of the goal (Snyder, 2000).  
 There are three components: goals, agentic thinking, and pathways 
thinking. A goal can be short-term or long-term, specific or vague, but a goal 
must be perceived as valuable enough to justify being an object of focus (Snyder, 
2002).  There must be some possibility, and some degree of uncertainty, of 
achieving the goal; an unattainable goal would not inspire hope and a goal that is 
certain to happen effortlessly would not inspire any motivational thought (Snyder, 
2000). Agency, the perceived ability to execute the steps to achieve the goal, is 
the motivational element of hope (Snyder, 2002). When barriers arise, agentic 
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thinking enables the individual to stay motivated to create solutions to bypass 
those barriers (Snyder, 2000).  Pathways thinking consists of strategizing how to 
get from point A to point B and creating connections between one’s actions in the 
past, present, and future that are relevant to the individual’s goals (Snyder, 2002).  
Successful pathways thinking creates alternative routes when encountering 
obstacles (Snyder, 2000).  Agentic thinking and pathways thinking are interactive 
and iterative cognitive processes that lead to the goal being attained or not 
attained (Snyder, 2000).   
 These cognitive processes, ideally, happen quickly. High-hope individuals 
have high agentic thinking and high pathways thinking; when they foresee a 
challenge, they are quick to take charge and find a way to overcome the challenge 
(Snyder, 2002). Conversely, low-hope individuals have low agentic thinking and 
low pathways thinking; they are slow to realize their capability to take action and 
slow to generate any solutions to the problem (Snyder, 2002). Mixed-hope 
individuals could have low agentic thinking and high pathways thinking or high 
agentic thinking and low pathways thinking (Snyder, 2002).   
 In McGeer’s (2004) view, hope is a process, though it is also integrated 
with the construct of agency. Hope is a necessary component of human agency, 
since hope is oriented toward the future and the actions that may be taken in the 
present in order to affect the future.  Learning to hope is inseparable from learning 
about one’s own agency as an individual, which is a process that starts at birth and 
continues throughout childhood.  In a process that McGeer calls “parental 
scaffolding,” an individual’s parents reflect and reiterate his or her own potential 
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back to him or her.  Later, agency-building continues as peers, rather than parents, 
perform ‘peer scaffolding’ by reflecting and reiterating the individual’s 
capabilities back to him or her, as the individual does for them reciprocally.  
Likewise, successful hoping has a social dimension, because only by empowering 
others with one’s own hope can one also be empowered by their hope (McGeer, 
2004).    
 According to McGeer (2004), hope can be wishful, willful, or responsive. 
Wishful hope is characterized by a low belief in one’s agency and an 
overdependence on external forces to insure the attainment of a goal.  An 
individual who wants to lose weight only by taking a weight loss medication and 
not making any other changes related to behavior or environment would be a 
wishful hoper, for example. Willful hope involves having an unrealistically high 
belief in one’s agency and allowing the goal to consume one’s identity, even to 
the extent of sacrificing relationships with other people (McGeer, 2004). The 
optimal type of hope is responsive hope, which includes a realistic view of one’s 
own agency and of the external forces that affect the attainment of a goal as well 
as the reciprocal empowering of others that generates empowerment back toward 
the individual (McGeer, 2004). 
 Viewing hope as an emotion is useful when exploring hope as an 
ubiquitous element of marketing campaigns for many products and services, such 
as stock market products, lottery tickets, weight loss products, self-help books, 
cosmetic surgical procedures, and visits with physicians and therapists for the 
purpose of resolving illnesses (MacInnis and de Mello, 2005).  Marketers in a 
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variety of industries purposely appeal to the consumer’s desire to feel hopeful. 
Monsanto, for example, uses the slogan “Food, Health, Hope” to sell its 
biotechnology products internationally (Drahos, 2004). Consumers tend to be 
susceptible to buying dangerous or ineffective weight-loss products because they 
are eager to believe in the promises presented in advertisements about the 
possibilities of achieving their goals through buying the product, which is the 
main focus; consumers do not stop to consider the lack of scientific evidence 
about the safety or efficacy of the product (MacInnis and de Mello, 2005).  
Companies design marketing campaigns that stimulate the emotion of hope, or a 
“yearning” for an outcome that is congruent with the consumer’s existing goals 
and that can be supplied by the product or service being sold. One marketing 
principle is to enhance the perceived importance of the product by connecting it 
with the attainment of the consumer’s ultimate goals; an effective marketing 
message for a weight loss product could be “Losing weight makes you healthier, 
increases yus  
self esteem, and gains you respect and admiration from others” (MacInnis and de 
Mello, 2005).   
   The United States, as an overweight society, is vulnerable to promises of 
hope from the weight loss industry. To judge weight loss products, consumers 
need evidence about them to be gathered by parties that do not have a financial 
interest in the products under scrutiny. Drahos (2004) asserts that social structures 
that provide the opportunities for a variety of groups to investigate public hope 
are more conducive to finding the truth about public hope. Pharmaceutical 
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companies, therefore, should not be the sole sponsors of pre-market and post-
market trials of weight-loss drugs since their profit-driven interests can affect how 
evidence is gathered with respect to the hypothesis (Drahos, 2004).   
 In the case of South Africa, in response to the Acquired Immune 
Deficiency Syndrome (AIDS) pandemic and the limited access to medicine 
caused by complying with international patent laws, the government passed a bill 
that gave the health minister some power in regulating access to the medicine 
supply (Drahos, 2004). The U.S. pressured South Africa strongly to repeal the bill 
and dozens of U.S. pharmaceutical companies began litigation processes against 
South Africa. Activists and non-governmental organizations conducted a global 
campaign that revealed the damage in other developing countries that resulted 
from supporting the pharmaceutical companies’ interests in upholding patent law, 
leading to limited access to medicines. Pharmaceutical companies withdrew from 
the litigation because the ‘access to medicines’ campaign raised widespread 
criticism about the economics of the patents, the drugs, the research, and the 
actual risks being assumed by the private sector when the research was mainly 
being done in the public sector.  The ‘access to medicines’ campaign achieved 
further reductions in the prices of AIDS antiretroviral treatments.  The 
contributions of the activities and NGOs, as additional voices of truth, 
counteracted the exploitation of public hope (Drahos, 2004). 
 There are many possible ways to channel the communal sense of hope to 
motivate individuals to achieve better health for them and for future generations: 
changing public policies regarding access to nutritious foods for people of all 
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income levels, removing corporate interests from the process of creating federal 
diet planning recommendations to make room for evidence-based practices, 
training journalists how to present scientific evidence about nutrition topics for 
the lay public, and educating consumers about how to process health and nutrition 
information presented in the mass media. Through public health marketing 
campaigns that create links between specific nutrition habits and individual health 
goals, hope can be used to inspire, instead of to betray.
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APPENDIX B 
CODEBOOK 
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Framing Weight-loss Drugs 
Newspaper Content Analysis Codebook 
Department of Nutrition 
Arizona State University  
 
 In this content analysis project, the goal is to document the media frames 
used to present the weight-loss drugs Xenical and Alli in articles in major U.S. 
newspapers during the time periods starting from each weight-loss drug’s date of 
approval by the U.S. Food and Drug Administration and ending six months after 
the date the weight-loss drug was released and made available to the public.  
 The primary selection criteria for articles will be the coverage of the 
weight-loss drugs Xenical or Alli or their generic name, orlistat.  News articles, 
feature articles, science/health articles, and business articles will be included.  
Corrections and quotations articles that mention the weight-loss drug in passing 
will be excluded. Coverage of the weight-loss drug will need to occupy at least 2 
full paragraphs to be included in the content analysis. Articles from non-U.S. 
newspapers will be excluded.  Duplicative articles will be included.  The 
minimum length of articles must be 200 words in order to qualify for this study.  
 Text-analysis software will be utilized to tabulate key words into 
frequency tables.  These tables will be used to create media frames.   
 
ARTICLENUMBER: As an article is selected for coding, it must be assigned an  
   article number.  Articles should be numbered as integers  
   beginning with 1.  
 
DUPLICATIVE:     Enter the code that indicates whether or not the article is a  
   duplicative article (e.g. an AP story or an article that was  
   previously published in another newspaper).  
 
To determine whether an article is duplicative or not, look 
at the “Author” field that appears below the newspaper 
name and above the text of the article.  An article is a 
duplicative article if Associated Press, Reuters, or other 
newswire service appears there, or if there is another 
publication’s name after the writer’s name that differs from 
the newspaper in which the article is printed.  Also, look at 
the first line of the article or in the “Dateline” field below 
the article for the article’s city of origin.  If the city of 
origin of the article differs from the newspaper’s city of 
origin, the article is a duplicative article.  
 
Code:  
 
1 = Yes  
2 = No  
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999 = Unknown 
 
Examples of duplicative articles:  
Author; Reuters News Service 
Author: The Associated Press  
Author: John Hendren, Associated Press writer  
Author: Knight-Ridder Newspapers (implies that the article 
has been published in other newspapers besides this one)  
Author: From Our Press Services 
Author: Marlene Cimons, Marilynn Marchione of the 
Journal Sentinel staff contributed to this report, Los 
Angeles Times (article is from the Milwaukee Journal-
Sentinel)  
Author: Marlene, Cimons, Los Angeles Times (article is 
from the Pittsburgh Post-Gazette) 
 
Examples of non-duplicative articles:  
Author: Record Searchlight  (article is from Redding 
Record Searchlight)   
Author: D’Ann Mabray Shippy, Karen Brooks, Star-
Telegram Writer (article is from Fort Worth Star-Telegram)  
 
Examples of unknown duplicative status:  
“NEW YORK – Weight conscious Americans…” (The city 
of origin of the article is New York, and the newspaper is 
the Contra Costa Times in Walnut Creek, CA, but the 
newspaper may have its own staff writer in New York)  
 
ARTICLETITLE:  Enter the title of the article as it appears on the print-out 
from the LexisNexis®  database. Do not correct any 
spelling or grammatical errors from LexisNexis®. 
 
Enter into SPSS as a string variable. 
 
NEWSPAPER: Enter the name of the newspaper as it appears on the print- 
   out from the LexisNexis® database. Do not correct any  
   spelling or grammatical errors from LexisNexis®.  
 
Enter into SPSS as a string variable. 
 
RANK:  Enter the rank of the newspaper on the 2008 list of the Top 
100 Daily Newspapers in the U.S. by Circulation in 
BurrellesLuce.  
 
 Code "0" to indicate a newspaper that was not on the list. 
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Enter into SPSS as a string variable. 
 
PAGENUMBER:  Enter the page number of the newspaper in which the 
article appears.  The page number should be coded using 
both letters and numbers, if applicable.  Use capital letters, 
e.g. enter “A1” whether the page number appears as “a1” or 
“A1”.  If the page number is listed as “PD2”, enter it as 
“PD2”.  
 
Enter into SPSS as a string variable. 
 
WORDCOUNT:  If the entire article is about the weight-loss drug, enter the 
word count of the article as it appears in the “Length” field 
in the search results screen of the LexisNexis®  database.  
If the article contains multiple news segments and only one 
of them is about the weight-loss drug, then copy and paste 
the segment about the weight-loss drug from LexisNexis® 
into Word and use the word count function to get the word 
count  
 
 This is a numerical variable. 
 
MONTH:  Enter the number that corresponds to the month of 
publication (e.g. for July 16, 2007, code 7).  Code:  
 
   1 = January  
   2 = February 
   3 = March 
   4 = April 
   5 = May 
   6 = June  
7 = July 
8 = August 
9 = September 
10 = October 
11 = November 
12 = December 
 
DATE:  Enter the date of publication as a two-digit number (e.g. for 
July 16, 2007, code 16).  
 
YEAR:  Enter the year of publication as a four-digit number. (e.g. 
for July 16, 2007, code 2007). 
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DAY: Enter the number that corresponds to the day of the week 
on which the article was published, which should be 
indicated in LexisNexis.   
If the article does not indicate the day of the week of its 
publication, refer to the website 
http://www.timeanddate.com/calendar/   
Code:   
 
1 = Sunday 
2 = Monday 
3 = Tuesday 
4 = Wednesday 
5 = Thursday 
6 = Friday  
7 = Saturday 
 
DRUGCODE: Enter numerical code for the weight-loss drug. Code:  
 
 1 = Xenical 
 2 = Alli  
 9 = Meridia 
  
RELEASE: Enter numerical code that corresponds to the timing of the 
article’s publication in relation to the date the weight-loss 
drug was released. 
 
The release date for Meridia was March 2, 1998.  
The release date for Xenical was April 26, 1999. 
The release date for Alli was June 15, 2007.  
 
 Code:   
 
 1 = Pre-release 
 2 = Post-release  
 
PERSONALSTMT Indicate whether or not the article mentions at least one 
personal statement, defined as an attribution or quote by an 
individual lay person (e.g. “person on the street”).   
To qualify as a personal statement, the quote must be from 
a lay person who does not have a title nor a role as a 
representative of an established (e.g. an obesity advocacy 
group). The statement may appear in quotation marks or as 
a paraphrased statement.  The content of the statement does 
not have to be about the weight-loss drug specifically.   
 
Code:  
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1 = Yes 
   2 = No  
 
Examples of personal statements:  
“It took the edge off  my appetite, gave me a feeling of 
fullness…” said Katie Philips, a participant in clinical trials 
of the drug.  
“In the two weeks since she’s been taking Meridia, she’s 
cut her food intake by half.  ‘(The drug) just tells you not to 
eat anymore’,” 
“’When you get to the point where you can’t fit into 
anything and you’re not mobile, you’re just desperate,’ said 
Ms. Hammond, who weighs over 300.”  
 
PROFSTMT1 Indicate whether or not the article mentions at least one 
attribution or quote from an individual  physician.  The 
statement may appear in quotation marks or as a 
paraphrased statement. Code:  
 
1 = Yes 
   2 = No  
 
The salutation “Dr.” is not sufficient to indicate the 
individual is a physician; it may, but does not have to, 
appear before the individual’s name.    
Examples of descriptions or titles that would indicate a 
statement from a physician:  
“medical director” 
 “internist” 
“cardiologist” 
“psychiatrist”  
“physician”  
“MD” (doctor of medicine)  
“medical resident” 
“resident”  
“medical intern”  
“intern”  
“DO” (doctor of osteopathy)  
 “…said cardiologist and researcher John A. Osborne”  
 
Do not assume that the individual is a doctor because he or 
she is affiliated with a medical institution such as a hospital 
or a medical school.   
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Examples of descriptions or titles that would NOT indicate 
a statement from a physician:  
“medical student” 
“chiropractor” 
“naturopath” 
“holistic healer” 
“homeopath”  
“psychotherapist” 
“psychologist”  
“PhD”  
“Dr. Jane Smith” (without an additional description 
qualifying her as a physician such as “surgeon” or other 
type of doctor)   
“…said the FDA’s Dr. James Bilstad”  
“Dr. John Foreyt of the Baylor College of Medicine”  
“Dr. Robert Eckel of the University of Colorado Health 
Sciences Center, vice chairman of the AHA’s nutrition 
committee”  
 
PROFSTMT2 Indicate whether or not the article mentions at least one 
attribution or quote from an individual registered dietitian, 
nutritionist, or dietitian. The statement may appear in 
quotation marks or as a paraphrased statement.Code:   
 
1 = Yes 
   2 = No  
 
PROFSTMT3 Indicate whether or not the article mentions at least one 
attribution or quote from an individual scientist. The 
statement may appear in quotation marks or as a 
paraphrased statement. Code:  
 
1 = Yes 
   2 = No  
 
The individual must be described as being actively engaged 
in research.  Do not assume that the individual is a scientist 
because he or she is affiliated with the FDA, a university, a 
research institute, or a medical institution such as a hospital 
or a medical school.   
 
Examples of descriptions or titles that would indicate a 
statement from a scientist:  
“leader of one of the studies”  
“involved with clinical trials”  
“principal investigator” 
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“…said cardiologist and researcher John A. Osborne”  
A professor engaged in research, not necessarily affiliated 
with the same research study 
 
Examples of descriptions or titles that would NOT indicate 
a statement from a scientist:  
“Dr. Jane Smith” 
“…said the FDA’s Dr. James Bilstad”  
“Dr. John Foreyt of the Baylor College of Medicine”  
“Dr. Robert Eckel of the University of Colorado Health 
Sciences Center, vice chairman of the AHA’s nutrition 
committee”  
 
 
PROFSTMT4 Indicate whether or not the article mentions at least one 
attribution or quote from an individual pharmacist. The 
statement may appear in quotation marks or as a 
paraphrased statement. 
Code:  
 
1 = Yes 
   2 = No  
 
PROFSTMT5 Indicate whether or not the article mentions at least one 
attribution or quote from an individual psychotherapist.  
The statement may appear in quotation marks or as a 
paraphrased statement. 
Code:  
 
1 = Yes 
   2 = No  
 
Examples of descriptions or titles that would indicate a 
statement from a psychotherapist:  
   “psychotherapist” 
   “counselor” 
   “psychologist” 
   “social worker” 
   “Weight Watchers leader”  
 
INDUSTRYSTMT Indicate whether or not the article mentions at least one 
attribution or quote from the manufacturer’s spokesperson.  
 The industry statement could be a quote from the 
manufacturer’s spokesperson, from printed material (e.g. a 
brochure about the weight-loss drug) produced by the 
manufacturer, or a statement (e.g. press release, 
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advertisement, television commercial) released by the 
manufacturer. The statement may appear in quotation 
marks or as a paraphrased statement. 
 
Code:  
 
1 = Yes 
   2 = No  
 
Examples of industry statements:  
“Meridia, the drug so anxiously awaited that dieters 
honored it with dozens of Internet sites before it was 
approved, is expected to be in most pharmacies by mid-
March, Knoll said Thursday”  
“Knoll intends to work closely with doctors and patients…”  
 
FDAROLE Indicate whether or not the article mentions the regulatory 
role of the FDA.   
 
Code:  
 
1 = Yes 
   2 = No  
 
Examples of indicators of the FDA’s regulatory role:  
“The FDA approved the drug”  
“The FDA urged doctors to use caution in prescribing 
Meridia…”  
“’This drug should not be used for those who want to lose 
simply a few pounds, “warned Dr. James Bilstad, FDA’s 
metabolic drug chief.  
 
BMISTDS Indicate whether or not the article mentions BMI standards 
for the use of this drug.  A relationship between height and 
weight may be stated rather than specific Body Mass Index 
scores. Code:  
 
1 = Yes 
   2 = No  
 
Examples of BMI standards:  
“The drug should be used only by people who run the risk 
of serous health problems because of obesity, such as a 
patient who stands 5 feet 5 inches and weights 180 pounds”  
“And it is only for the seriously obese, as measured by a 
body mass index – the relationship of weight to height – of 
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30 or greater, such as someone who is 5 feet, 6 inches and 
weighs 185 pounds.”  
 
SIDEEFFECTS  Indicate whether or not the article mentions side effects for 
the use of this drug.  Code:  
 
1 = Yes 
   2 = No  
 
WTLOSS  Indicate whether or not the article mentions a track record  
   of success or a specific promise or prediction about the  
   amount of weight loss either in the number of pounds,  
   inches, or a percentage of body weight.  
A promise of weight loss must be described as a 
quantifiable amount of weight, either in lbs., inches, or 
percentage of body weight lost.  Qualitative descriptions 
(e.g. “modest weight loss” do  not count as a promise of 
weight loss.  
Code:  
 
1 = Yes 
   2 = No  
 
MECHANISM Indicate whether or not the article states the mechanism by 
which the drug works.   
The mechanism by which the drug works must be explicitly 
stated (e.g. “appetite suppressant”).  A description of the 
drug’s mechanism as merely similar or different from 
another drug’s mechanism does not qualify (e.g. “works 
differently from other diet drugs”). 
 
Code:  
 
1 = Yes 
   2 = No  
  
CONTRAIND  Indicate whether or not the article mentions who should not 
use the drug.  
 
In order to code “yes” for contraindications, the article 
must state at least one condition or disease state that is not 
compatible with usage of the drug. Examples of 
contraindications include pregnancy, liver disease, 
hypertension, and cardiovascular disease.  If the article 
does not state who should not take the drug, then code 
“no”. 
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Code:  
 
1 = Yes 
   2 = No  
 
DIETRXS  Indicate whether or not the article includes 
recommendations for dietary changes with the use of this 
drug.  There must be a stated connection between the use of 
the drug and at least one dietary change.   
  
 Code:  
 
1 = Yes 
   2 = No  
  
Examples of recommendations for dietary changes:  
“Knoll Pharmaceutical’s sibutramine, to be sold under the 
brand name Meridia, appears to cause a modest weight 
reduction – usually about 5 percent – when taken together 
with diet and exercise.” 
 
Examples that DO NOT qualify as recommendations for 
dietary changes:  
“Many doctors say that like Weight Watchers and other 
diet centers, they, too, are helping former diet-drug patients 
shed pounds the old-fashioned way:  by exercising and 
eating right.” 
 
 
PHYSRXS  Indicate whether or not the article includes 
recommendations for changes in physical activity with the 
use of this drug.  Code:  
 
1 = Yes 
   2 = No  
 
Examples of recommendations for changes in physical 
activity:  
“Knoll Pharmaceutical’s sibutramine, to be sold under the 
brand name Meridia, appears to cause a modest weight 
reduction – usually about 5 percent – when taken together 
with diet and exercise.” 
 
COUNRXS  Indicate whether or not the article includes 
recommendations for person-to-person psychological or 
 149 
nutritional counseling with the use of this drug.  Counseling 
may be performed by a psychologist, psychotherapist, 
social worker, Weight Watchers leader, nutritionist, or 
dietitian.   
 
Code:  
 
1 = Yes 
   2 = No  
 
   Examples of counseling recommendations:  
   “cognitive behavioral therapy”  
   Other approaches to psychotherapy  
 
Examples that do NOT qualify as counseling 
recommendations:  
   “behavior modification program” 
   “behavior modification plan”  
 
COST Indicate whether or not the article mentions the cost of the 
drug.  The cost of ancillary treatments may be included in 
this amount.  Global sales information does not qualify as 
cost. Code:  
 
1 = Yes 
   2 = No  
 
Examples of mentions of cost:  
“The new drug, plus vitamins and supplements and 
behavior modification counseling, costs her $200 a month.” 
RULES 
 
1. Page number should be coded using both letters and numbers, if 
applicable. 
2. The pre- and post- release variable should use the release dates as 
follows:  
a. The release date for Meridia was March 2, 1998.  (The FDA 
approval date was November 22, 1997.1) 
b. The release date for Xenical was April 26,1999.  (The FDA 
approval date was April 23, 1999.2)  
                                                
1 U.S. Food and Drug Administration Center for Drug Evaluation and Research.  Accessed 18 July 
2008. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails 
2 U.S. Food and Drug Administration Center for Drug Evaluation and Research.  Accessed 18 July 
2008. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
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c. The release date for Alli was June 14, 2007.  (The FDA approval 
date was February 7, 2007.3)   
3. To qualify as a personal statement, the quote must be from a lay 
person who does not have a title nor a role as a representative of an 
established (e.g. an obesity advocacy group).  
4. The industry statement could be a quote from the manufacturer’s 
spokesperson, from printed material (e.g. a brochure about the weight-
loss drug) produced by the manufacturer, or a statement (e.g. press 
release, advertisement, television commercial) released by the 
manufacturer.  
5. An attribution statement by a layperson, health professional or by a 
representative of the industry can be a statement in quotation marks or 
a paraphrased statement. 
6. A promise of weight loss must be described as a quantifiable amount 
of weight, either in lbs., inches, or percentage of body weight lost.  
Qualitative descriptions (e.g. “modest weight loss” do  not count as a 
promise of weight loss.  
7. The mechanism by which the drug works must be explicitly stated 
(e.g. “appetite suppressant”).  A description of the drug’s mechanism 
as merely similar or different from another drug’s mechanism do not 
qualify (e.g. “works differently from other diet drugs”). 
8. In order to code “yes” for contraindications, the article must state at 
least one condition or disease state that is not compatible with usage of 
the drug. Examples of contraindications include pregnancy, liver 
disease, hypertension, and cardiovascular disease.  If the article does 
not state who should not take the drug, then code “no”. 
9. Cost is defined as the cost of the drug to an individual consumer. 
Global sales information about the drug does not count as cost.  
10. Missing or unknown values will be indicated using the code “999”  
                                                
3 U.S. Food and Drug Administration Center for Drug Evaluation and Research.  Accessed 18 July 
2008. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails 
